US Pat. No. 10,918,715

TREATMENT OF SEVERE COMMUNITY ACQUIRED PNEUMONIA

BIOTEST AG, Dreieich (DE...

1. A method of treating severe Community Acquired Pneumonia (sCAP) in a patient comprising administering to the patient a therapeutically effective amount of a human plasma-derived IgM-enriched immunoglobulin preparation, said immunoglobulin preparation not having been treated with beta-propiolactone said patient has a serum C-Reactive Protein (CRP) level of at least 70 mg/L and/or a serum procalcitonin (PCT) level of at least 2.0 ng/ml.
US Pat. No. 10,918,971

MUTATED IMMUNOGLOBULIN-BINDING PROTEIN

1. A matrix for affinity chromatography, comprising a plurality of ligands coupled to a solid support,wherein the ligands comprise an immunoglobulin-binding protein, or multimer thereof that binds to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), and
wherein at least one of N23 and N43 of a parental immunoglobulin-binding protein defined by SEQ ID NOS:1 or 2 have been mutated to amino acid residues selected from A, I, S, T, E, or H,
wherein the N23 and N43 asparagine residues can be mutated to amino acid residues that are the same or different from each other, and
wherein the mutations have conferred an increased chemical stability at alkaline pH-values compared to the parental immunoglobulin-binding protein.
US Pat. No. 10,920,252

PRODUCTION OF FATTY ACID ESTOLIDES

Stichling Wageningen Rese...

1. A one-pot method for producing one or more esters of one or more hydroxy-fatty acids in a single aqueous buffered, cell-free reaction medium said method comprising:(a) providing in said single aqueous buffered, cell-free reaction medium at least one unsaturated fatty acid with a cis C9-C 10 double bond;
(b) reacting said at least one unsaturated fatty acid with a cis C9-C10 double bond in said single aqueous buffered, cell-free reaction medium with an isolated cell-free oleate hydratase to produce at least one hydroxy-fatty acid; and
(c) producing one or more esters of said at least one hydroxy-fatty acid in said single aqueous buffered, cell-free reaction medium by means of an isolated lipase, wherein the isolated lipase and the isolated cell-free oleate hydratase are contemporaneously present in the single aqueous buffered, cell-free reaction medium, wherein to the extent the single aqueous buffered, cell-free reaction medium comprises an organic solvent, the organic solvent is not present in an amount such that the hydratase enzyme is rendered inactive in the reaction medium to produce the at least one hydroxy-fatty acid.
US Pat. No. 10,918,716

TRIPLE COMBINATION THERAPY FOR TREATING CROHN'S DISEASE

Millennium Pharmaceutical...

1. A method of treating Crohn's disease (CD) in a human patient in need thereof, wherein the method comprises:selecting a high-risk CD human patient, and
administering to the high-risk CD human patient, a triple combination therapy comprising a humanized anti-?4?7 antibody, adalimumab, and methotrexate,
wherein the triple combination therapy is administered to the high-risk CD human patient according to the following dosing regimen:
a. an initial dose of 300 mg of the humanized anti-?4?7 antibody as an intravenous infusion, followed by a second subsequent dose of 300 mg of the humanized anti-?4?7 antibody as an intravenous infusion at about two weeks after the initial dose; followed by a third subsequent dose of 300 mg of the humanized anti-?4?7 antibody as an intravenous infusion at about six weeks after the initial dose;
b. an initial dose of 160 mg of adalimumab as a subcutaneous injection, followed by a second subsequent dose of 80 mg of adalimumab as a subcutaneous injection, followed by a third subsequent dose of 40 mg of adalimumab at about four weeks after the initial dose; and
c. an initial dose of 15 mg of methotrexate orally
wherein the dosing regimen results in endoscopic remission,
further wherein the anti-?4?7 antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the ?4?7 complex, wherein the antigen-binding region comprises the CDRs:Light chain: CDR1 SEQ ID NO:7CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; andHeavy chain: CDR1 SEQ ID NO:4CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.
US Pat. No. 10,920,253

ENZYMATIC PRODUCTION OF ACETYL PHOSPHATE FROM FORMALDEHYDE

Scientist of Fortune, S.A...

1. A method of producing acetyl phosphate, wherein the method comprises:(a) contacting formaldehyde and phosphate with a phosphoketolase (EC 4.1.2.9), a fructose-6-phosphate phosphoketolase (EC 4.1.2.22) or a Sulfoacetaldehyde acetyltransferase (EC 2.3.3.15); and
(b) enzymatically converting formaldehyde and phosphate into acetyl phosphate by the phosphoketolase (EC 4.1.2.9), the fructose-6-phosphate phosphoketolase (EC 4.1.2.22) or the Sulfoacetaldehyde acetyltransferase (EC 2.3.3.15).
US Pat. No. 10,920,254

METHODS AND MATERIALS FOR PRODUCING 5 AND 7-CARBON MONOMERS

INV Nylon Chemicals Ameri...

1. A method of producing 3-oxo-7-hydroxyheptanoyl-CoA or a salt thereof, said method comprising enzymatically converting 5-hydroxypentanoyl-CoA to 3-oxo-7-hydroxyheptanoyl-CoA using a polypeptide having the activity of a ?-ketothiolase classified under EC 2.3.1.16 or EC 2.3.1.174.
US Pat. No. 10,918,718

SONOSENSITIVE THERAPEUTIC OR DIAGNOSTIC AGENT

Oxsonics Limited, Oxford...

1. A method of diagnosis or treatment of a human or animal subject, which method comprises administering to said subject an effective amount of an agent,wherein the agent comprises a therapeutic or diagnostic component which is covalently bound to a dense component, the dense component having a density greater than that of the therapeutic or diagnostic component,
wherein the method comprises administering to the subject a further agent which is a cavitation initiator, said cavitation initiator being a substance comprising one or more gas or vapor filled cavities or bubbles, and
wherein the method further comprises exposing the subject to ultrasound, wherein the cavitation initiator undergoes inertial cavitation in the subject.
US Pat. No. 10,919,999

METHOD FOR PREPARING AN AQUEOUS DISPERSION OF MULTISTAGE POLYMER PARTICLES

Rohm and Haas Company, C...

1. A method for preparing an aqueous dispersion of multistage polymer particles comprising the steps of:a) contacting under emulsion polymerization conditions an aqueous dispersion of core polymer particles with first monomers to form an aqueous dispersion of core/first stage polymer particles; and
b) contacting under emulsion polymerization conditions the aqueous dispersion of core/first stage polymer particles with second monomers to form the aqueous dispersion multistage polymer particles; and
c) neutralizing the aqueous dispersion of multistage polymer particles with a base; wherein
the core polymer particles comprise from 25 to 60 weight percent structural units of a carboxylic acid monomer or a salt thereof, from 40 to 75 weight percent structural units of a nonionic ethylenically unsaturated monomer, and up to a total of 15 weight percent structural units of styrene and a high Tg hydrophobic monomer; wherein
the high Tg hydrophobic monomer is one or more monomers selected from the group consisting of cyclohexyl methacrylate, isobornyl methacrylate, 4-t-butyl methacrylate, t-butylstyrene, and n-butyl methacrylate;
the first monomers comprise from 5 to 15 weight percent of an carboxylic acid monomer or a salt thereof; 2) from 45 to 55 weight percent styrene; 3) from 37 to 47 weight percent methyl methacrylate or the high Tg hydrophobic monomer or a combination thereof; and
the second monomers comprise from 80 to 99.9 weight percent styrene and from 0.1 to 0.5 weight percent of a multiethylenically unsaturated monomer; wherein,
the weight-to-weight ratio of the core polymer particles to the sum of the first and second monomers is in the range of from 1:9 to 1:20; and the weight-to-weight ratio of the first monomers to the second monomers is in the range of from 1:3 to 1:8;
with the proviso that the core/first stage polymer particles comprise, based on the weight of the core/first stage polymer particles, from 2 to 15 weight percent structural units of the high Tg hydrophobic monomer.
US Pat. No. 10,920,255

PROCESS FOR PRODUCING L-METHIONINE FROM METHIONAL

Evonik Operations GmbH, ...

1. A method for producing an L-amino acid, comprising:reacting a mixture comprising an aldehyde, carbon dioxide, a decarboxylase, a corresponding decarboxylase cofactor, and
(a) at least one donor amino acid and an aminotransferase, and/or
(b) NADH, ammonia and/or an ammonium salt and an amino acid dehydrogenase,
thereby producing said L-amino acid or a salt thereof,
wherein the L-amino acid produced is L-methionine and the aldehyde is 3-(methylthio)-propanal (methional),
wherein the decarboxylase is at least one member selected from the group consisting of pyruvate decarboxylase PDC1, which originates from Saccharomyces cerevisiae, phenylpyruvate decarboxylase ARO10, which originates from Saccharomyces cerevisiae, and branched chain decarboxylase KdcA, which originates from Lactococcus lactis,
wherein the aminotransferase, if present, is at least one member selected from the group consisting of methionine aminotransferase YbdL, which originates from E. coli, and aromatic aminotransferase Aro8, which originates from Saccharomyces cerevisiae, and
wherein the amino acid dehydrogenase, if present, is at least one member selected from the group consisting of leucine dehydrogenase (LeuDH), which originates from Bacillus sphaericus, and phenylalanine dehydrogenase (PheDH), which originates from Thermoactinomyces intermedius.
US Pat. No. 10,920,256

PROCESS

Vestlandets Innovasjonsse...

1. A process for producing neosaxitoxin in a host cell, the process comprising the steps:(A) culturing a host cell which comprises nucleic acid molecules encoding a phosphopantetheinyltransferase (PPTase) and encoding the Sxt polypeptides A, B, D, G, H, I, S, T, U, V, W and X in a culture medium in the presence of the substrates:
(i) S-adenosylmethionine,
(ii) arginine
(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and
(iv) carbamoyl phosphate,
wherein the host cell is a recombinant prokaryotic cell or a recombinant yeast cell,
and wherein the host cell does not comprise nucleic acid molecules encoding the Sxt polypeptides C, F, J, K, L, M, P, Q, R and ORF24,
under conditions which are suitable for the production of neosaxitoxin; and optionally
(B) isolating and/or purifying neosaxitoxin from the host cells or from the culture medium.
US Pat. No. 10,918,721

DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY

Immunomedics, Inc., Morr...

1. A method of treating a Trop-2 positive cancer comprising administering to a human patient with a Trop-2 positive cancer an antibody-drug conjugate (ADC) sacituzumab govitecan; wherein the ADC is administered at a dosage of between 6 mg/kg and 16 mg/kg, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the ADC.
US Pat. No. 10,920,258

CHEMO-ENZYMATIC SYNTHESIS OF SEMAGLUTIDE, LIRAGLUTIDE AND GLP-1

ENZYPEP B.V., Geleen (NL...

1. A method for synthesising a peptide comprising the sequence His-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Y-Glu-Phe-Ile-Ala-Trp-Leu-Val-Z-Gly-Arg-Gly, comprising enzymatically coupling(a) a peptide C-terminal ester or thioester comprising a first peptide fragment comprising the sequence His-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-(thio)ester (SEQ ID NO: 11); and
(b) a peptide nucleophile having an N-terminally unprotected amine comprising a second peptide fragment comprising the sequence H-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Y-Glu-Phe-Ile-Ala-Trp-Leu-Val-Z-Gly-Arg-Gly (SEQ ID NO: 12)
wherein
X is Ala or an ?-amino-isobutyric acid (Aib) residue;
Y is Lys, which Lys has a free side-chain ?-amino group or of which Lys the side-chain ?-amino group is protected with a protective group or of which Lys the side-chain ?-amino group is functionalized with an amino acid or another functional group selected from the group consisting of ?-Glu-OH, Pal-?-Glu-OH, AEEA-AEEA-?-Glu-OH and AEEA-AEEA-?-Glu-N-17-carboxyheptadecanoyl-OH,
wherein Pal is palmitoyl and AEEA-AEEA is -2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2-(2-aminoethoxy)ethoxy]acetyl; and
Z is Arg or Lys;
which enzymatic coupling is catalysed by a ligase, wherein the ligase is a subtilisin BPN? variant or a homologue thereof, which comprises the following mutations compared to subtilisin BPN? represented by SEQ ID NO: 2:
a deletion of the amino acids corresponding to positions 75-83;
a mutation at the amino acid position corresponding to S221, the mutation being S221C or S221 selenocysteine;
wherein the amino acid positions are defined according to the sequence of subtilisin BPN? represented by SEQ ID NO:2.
US Pat. No. 10,918,722

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC....

1. A method of treating migraine, comprising orally administering a combination to a human being who is suffering from an acute attack of migraine pain or migraine aura, wherein the combination comprises: 1) a complex of a meloxicam and a sulfobutylether-?-cyclodextrin; 2) a bicarbonate; and 3) about 8 mg to about 13 mg of a rizatriptan, based upon the weight of the free base form of rizatriptan, wherein the combination is in a single dosage form, wherein the single dosage form is structured so that orally administering the single dosage form to healthy human subjects would result in a mean Tmax of meloxicam of 110 minutes or less, and an AUC0-24 of meloxicam of about 30 ?g·hr/mL to about 50 ?g·hr/mL, wherein the human being is also suffering from vomiting with migraine pain or migraine aura; and wherein 2 hours after the combination is orally administered, the human being experiences greater relief from vomiting than the human being would experience 2 hours after the same amount of the rizatriptan is orally administered alone.
US Pat. No. 10,920,003

MULTI-COMPONENT COPOLYMER, RUBBER COMPOSITION, CROSSLINKED RUBBER COMPOSITION AND RUBBER ARTICLE

BRIDGESTONE CORPORATION, ...

1. A multi-component copolymer comprising conjugated diene units, non-conjugated olefin units and aromatic vinyl units, which has a weight-average molecular weight of 100,000 to 2,000,000, wherein:a peak top molecular weight of chain parts, obtained by ozonolyzing the conjugated diene units contained in the multi-component copolymer with an ozonolysis method and each containing one or more of the non-conjugated olefin units and/or one or more of the aromatic vinyl units, is less than 2,000;
a 1,2 vinyl bond content in the conjugated diene units of the multi-component copolymer is 1.4% or more;
the non-conjugated olefin units consist exclusively of ethylene units; and
a content of any unit other than the conjugated diene units, the non-conjugated olefin units and the aromatic vinyl units in the multicomponent copolymer is 0 mol %.
US Pat. No. 10,918,723

COLON CLEANSING COMPOSITIONS AND METHODS OF USE

Norgine BV, Amsterdam (N...

1. A method of cleansing the colon of a subject comprising:administering to the subject an effective amount of a first colon cleansing solution;
administering to the subject an effective amount of a second colon cleansing solution,
the second colon cleansing solution comprising:
a) 350 650 mmol per litre ascorbate anion provided by a mixture of:
(i) ascorbic acid and
(ii) one or more salts of ascorbic acid
the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and
b) 10 to 200 g per litre polyethylene glycol, whereby the first colon cleansing solution is taken over a time period t(d1) followed by optional additional clear fluid over a time period t(cf1), and then following a time interval t(dose interval), the second colon cleansing solution is taken over a time period t(d2) followed by optional additional clear fluid over a time period t(cf2), whereby the subject undergoes a surgical, therapeutic or diagnostic procedure at a time t2 after the beginning of the colon cleansing method, and whereby the time interval after the completion of the second additional clear fluid and the start of the surgical, therapeutic or diagnostic procedure is t(procedure interval).
US Pat. No. 10,920,260

METHODS AND DEVICES FOR ASSESSMENT OF MITOCHONDRIAL FUNCTION

Erasmus University Medica...

1. A non-invasive method of measuring the lifetime of the first excited triplet-state (TAUT1) of endogenous protoporphyrin IX (PpIX) ex vivo or in vivo in mitochondria in cells in a sample volume of skin tissue of a subject, the method comprising:administering 5-aminolevulinic acid to the skin cells in said sample volume;
repetitively or continuously measuring fluorescence of protoporphyrin IX (PpIX) in mitochondria in the skin cells in said sample volume of skin tissue, using a device comprising an excitation light source directed to illuminate said sample volume, a light detector arranged to detect fluorescence from said sample volume, and a pressure pad for applying local pressure on said sample volume;
restricting or ceasing the supply of oxygen to the cells in said sample volume of skin tissue by applying local, positive pressure on the tissue to thereby occlude microvessels comprised in said said sample volume of skin;
repetitively or continuously measuring the lifetime of the first excited triplet state (TAUT1) of endogenous protoporphyrin IX (PpIX) in mitochondria in cells in said sample volume of skin tissue using said device, whereby at least two measurements are performed during said restricting or ceasing the supply of oxygen to the cells in said sample volume of skin tissue;
discontinuing applying local, positive pressure to said sample volume of skin tissue through said pressure pad to thereby discontinue said restricting or ceasing the supply of oxygen to the cells in said sample volume of skin tissue; and
repetitively or continuously measuring the lifetime of the first excited triplet state (TAUT1) of endogenous protoporphyrin IX (PpIX) in mitochondria in cells in said sample volume of skin tissue.
US Pat. No. 10,918,724

DERMOCOSMETIC COMPOSITIONS INCLUDING GLYCEROL-SEBACATE

THE SECANT GROUP, LLC, T...

1. A method of skin care comprising:applying a dermocosmetic composition to a skin surface, the dermocosmetic composition comprising:
at least one additive comprising at least one active ingredient; and
at least one glycerol-sebacate component having repeating units of (glycerol sebacate);
wherein the at least one additive is covalently attached to the glycerol-sebacate component; and
wherein the applying comprises applying the dermocosmetic composition as a dermal patch to the skin surface based on Langer's lines.
US Pat. No. 10,920,005

RUBBERY POLYMER, GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION

TECHNO-UMG CO., LTD., To...

1. A graft copolymer (B-I) produced by grafting at least one vinyl monomer (b-I) selected from the group consisting of aromatic vinyl, alkyl (meth)acrylate, and vinyl cyanide to a rubbery polymer mixture including a rubbery polymer (A-I) and a hydrophobic substance, the rubbery polymer (A-I) including an alkyl (meth)acrylate unit and a multifunctional monomer unit copolymerizable with alkyl (meth)acrylate, the hydrophobic substance having a kinematic viscosity of 5 mm2/s or more at 40° C. or a kinematic viscosity of 2 to 4 mm2/s at 100° C., the hydrophobic substance comprising a hydrocarbon.
US Pat. No. 10,920,261

REPEATED FED-BATCH CULTURE METHODS

MARA RENEWABLES CORPORATI...

1. A repeated fed batch method of culturing an oil-producing Thraustochytrid microorganism comprisinga. a cycle of steps comprising:
(1) providing a container comprising one or more oil-producing Thraustochytrid microorganisms and medium, wherein the oil-producing Thraustochytrid microorganisms and medium form a start volume;
(2) culturing the oil-producing Thraustochytrid microorganisms in the medium in the container by a fed-batch method comprising:
(a) culturing the oil-producing Thraustochytrid microorganisms under conditions that favor biomass production; and
(b) culturing the oil-producing Thraustochytrid microorganisms of step (a) under conditions that favor lipid production until the culture completes fermentation, and reaches a threshold volume when fermentation is complete, wherein the threshold volume is greater than the start volume and wherein the culturing comprises feeding one or more carbon sources to the culture;
(3) harvesting a portion of the threshold volume of the culture from the container to leave a residual volume in the container that is 20% to 40% of the start volume;
(4) adding fresh medium to the container in an amount to return the volume of the culture to the start volume; and
b. repeating the steps of the cycle one or more times.
US Pat. No. 10,918,725

OPHTHALMIC COMPOSITION COMPRISING REBAMIPIDE AND METHOD FOR PREPARING THE SAME

SAMJIN PHARMACEUTICAL CO....

1. An ophthalmic composition comprising:rebamipide;
consisting of a single amino acid, wherein the single amino acid consists of arginine;
a buffering agent, the ophthalmic composition being transparent solution and preventing the formation of a precipitate layer; and
wherein the pH range of the ophthalmic composition is between 7 and 8, the ophthalmic composition being transparent and free of precipitation of said rebamipide for at least 16 weeks.
US Pat. No. 10,920,007

URETHANE RESIN COMPRISING A POLYROTAXANE AND POLISHING PAD

TOKUYAMA CORPORATION, Ya...

1. A urethane resin obtained by polymerizing a polymerizable composition, which comprises (A) a polyrotaxane having a composite molecular structure comprising an axial molecule and a plurality of cyclic molecules clathrating the axial molecule, wherein side chains having a group with active hydrogen which are introduced into at least some of the cyclic molecules, and (B) a polyiso(thio)cyanate compound,wherein the polyiso(thio)cyanate compound (B) contains (B2) a urethane prepolymer having an iso(thio)cyanate group at the end of the molecule which is obtained by reacting (C1) a bifunctional active hydrogen-containing compound having two groups with active hydrogen in the molecule with (B1) a bifunctional iso(thio)cyanate group-containing compound having two iso(thio)cyanate groups in the molecule.
US Pat. No. 10,920,263

METHODS, COMPOSITIONS AND KITS FOR DETERMINING CLEANNESS OF A SURFACE

Sani-Marc Inc., Victoria...


wherein the stabilizer is propylene glycol, the solvent is isopropanol and the surfactant is Ethoxylated C12-15 alcohols; and
a developer solution comprising hydrogen peroxide and about 0.05% w/w to about 10% w/w foaming agent selected from the group consisting of decylamine oxide, lauramine oxide, myristyl dimethylamine oxide, and cocoamidopropylamine oxide
wherein the enzymatic solution and/or the developer solution is(are) contained in a handheld vaporizer or handheld spray bottle.
US Pat. No. 10,918,727

PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE

ICURE BNP CO., LTD., Eum...

1. A composition comprising a peptide consisting of the following amino acid sequence and a target substance, wherein the peptide is an active ingredient for delivering the target substance into living tissue or blood:R1-R2-R3-R4-R5-R6-R7-R8-R9-R10
wherein
R1 is M,
R2 is I,
R3 is I,
R4 is F,
R5 is R,
R6 is L,
R7 is L, P, H or A,
R8 is I, L, P, H or A,
R9 is S, E or Y, and
R10 is H, K, R, L or P; wherein optionally a peptide selected from the group consisting of a dipeptide, tripeptide or tetrapeptide of K is attached to R10.
US Pat. No. 10,920,008

THERMAL-CURABLE RESIN COMPOSITION, AND PRE-PREG, METAL-CLAD LAMINATE AND PRINTED CIRCUIT BOARD MANUFACTURED USING THE SAME

TAIWAN UNION TECHNOLOGY C...

1. A thermal-curable resin composition, comprising:(A) a thermal-curable resin component, which comprises:
(a1) a bismaleimide resin;
(a2) a cyanate ester resin; and
(a3) an epoxy resin,
wherein the cyanate ester resin (a2) and the epoxy resin (a3) are respectively, based on the dry weight, in an amount ranging from 75 parts by weight to 150 parts by weight and from 25 parts by weight to 50 parts by weight per 100 parts by dt weight of the bismaleimide resin (a1); and
(B) a filler,
wherein the cyanate ester resin (a2) is selected from the group consisting of 2,2-bis(4-cyanooxyphenyl)propane, 4,4?-ethylidene bisphenylenecyanate, 4,4?-dicyanooxybiphenyl, bis(4-cyanooxy-3,5-dimethylphenyl)methane, bis(4-cyanooxyphenyl) sulfide, bis(4-cyanooxyphenyl) ether, a prepolymer of bisphenol A dicyanate ester, 1,1-bis(4-cyanooxyphenyl)ethane, 1,1-bis(4-cyanooxyphenyl)methane, 1,3-bis(4-cyanooxyphenyl-1-(methylethylidene)) benzene, bis(4-cyanooxyphenyl)-2,2-butane, 1,3-bis[2-(4-cyanooxyphenyl)propyl]benzene, tris(4-cyanooxyphenyl)ethane, cyanated phenol, an adduct of cyanated phenol dicyclopentadiene, and combinations thereof,
wherein the filler (B) is in an amount ranging from 43 parts by weight to 47 parts by weight per 100 parts by weight of the dry weight of the resin composition; and
wherein the thermal-curable resin composition has a dynamic viscosity of not higher than 800 Pa·s after being brought into a semi-cured state (B-stage), and the thermal-curable resin composition has a dissipation factor (Df) of not higher than 0.006 at 10 GHz after being cured completely.
US Pat. No. 10,920,264

ACYL-COA DEHYDROGENASES MICRO/NANO ENZYME ASSAY

1. A method of quantifying acyl-coenzyme A dehydrogenase (ACAD) activity in a cell sample comprising:a. measuring a baseline fluorescence of an electron transfer flavoprotein (ETF) in a reaction mixture comprising lysed cells of the cell sample in an open-to-air well of a multi-well vessel by exposing the ETF to light of an excitatory wavelength and measuring fluorescence at an emission wavelength;
b. adding a coenzyme A (CoA) substrate for a specific ACAD to the reaction mixture; and
c. monitoring a change in fluorescence of the ETF at one or more time points after addition of the CoA substrate to the reaction mixture by comparing the baseline fluorescence of the ETF to the fluorescence of the ETF at the one or more time points after addition of the CoA substrate to the reaction mixture,
wherein a loss of fluorescence of the ETF indicates the presence of an ACAD in the sample, and
wherein the reaction mixture of step a is subjected to deaeration prior to measuring the baseline fluorescence, and wherein measuring the baseline fluorescence, adding a CoA substrate, and monitoring the change in fluorescence are carried out in an air-containing environment.
US Pat. No. 10,918,729

OSTEOSTIMULATING ELASTOMERIC BONE FILLING COMPOSITIONS

THE SECANT GROUP, LLC, T...

1. A bone filling composite comprising:a bone filler comprising:
microparticles of at least one elastomeric material comprising a poly(glycerol sebacate)-based thermoset; and
a filler dopant in the at least one elastomeric material; and
a carrier material mixed with the bone filler, the carrier material comprising:
a poly(glycerol sebacate) resin; and
at least one carrier dopant comprising glycerol and tricalcium phosphate.
US Pat. No. 10,920,266

DEVICE FOR REAL-TIME MEASUREMENT OF BACTERIA BY ATP DETECTION

KOREA INSTITUTE OF SCIENC...

1. A device for real-time measurement of bacteria, the device comprising:at least two reaction portions, each having a reagent for adenosine triphosphate (ATP) detection immobilized thereon;
a flexible support portion configured to support the at least two reaction portions;
a rotational shaft connected to the support portion and configured to move the support portion; and
a sample supply portion configured to supply a sample to each of the reaction portions,
wherein the at least two reaction portions comprise a reagent for ATP detection comprising luciferase and luciferin and a member configured to dry and immobilize the reagent, and
wherein the at least two reaction portions are arranged on the support portion at regular intervals.
US Pat. No. 10,923,707

DRY PROCESS METHOD FOR PRODUCING ELECTRODES FOR ELECTROCHEMICAL DEVICES AND ELECTRODES FOR ELECTROCHEMICAL DEVICES

FLORIDA STATE UNIVERSITY ...

1. A method of making an electrode for an electrochemical cell, comprising the steps of:providing an electrode composite comprising from 70-98% active material, from 0-10% conductive material additives, and from 2-20% polymer binder, based on the total weight of the electrode composite, said composite being devoid of polytetrafluoroethylene;
mixing the electrode composite, wherein the mixing step further comprises the step of providing a solvent for the binder and dissolving the binder in the solvent to provide a binder solution, and then adding the active material particles and conductive material additives to the binder solution in a ratio of from 10:1 to 1:5, by weight;
compressing the electrode composite into an electrode composite sheet;
applying the electrode composite sheet to a current collector with pressure to form an electrode, wherein the electrode possesses positive characteristics for adhesion according to ASTM standard test D3359-09e2, entitled Standard Test Methods for Measuring Adhesion by Tape Test, and wherein the electrode composite sheet and the electrode possess positive characteristics for flexibility according to the Mandrel Test.
US Pat. No. 10,918,730

PEGYLATED BIOACTIVE PEPTIDES AND USES THEREOF

GRIFFON PHARMACEUTICALS I...


wherein:
X1 is Tyr, His, N-methyl Tyr or Desamino Tyr;
X2 is Ala, D-Ala, Ser or alpha aminoisobutyric acid (Aib);
X8 is Asn, Asp, Ala, Gln, Ser or Aib;
X9 is Ser, Asp, Ala or Cys conjugated to a PEG polymer of less than or equal to 5 kDa;
X11 is Arg or L-Homoarginine (Har);
X12 is Lys or Orn;
X15 is Gly or Ala;
X18 is Ser or Ala;
X20 is Arg or Har;
X21 is Lys or Orn;
X22 is Leu, Val, Ala or Cys conjugated to a PEG polymer of less than or equal to 5 kDa;
X24 is Gln or Cys conjugated to a PEG polymer of less than or equal to 5 kDa;
X25 is Asp or Ala;
X26 is Ile or Ala;
X27 is Met, Leu or Norleucine;
X28 is Ser, Ala or Cys conjugated to a PEG polymer of less than or equal to 5 kDa;
X29 is Lys, Arg, Orn, Har or Agmantine; and
X30 is an NH2 group or Asn-NH2;
wherein at least one of X9, X22, X24 and X28 is Cys conjugated to a PEG polymer of less than or equal to 5 kDa;
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,918,731

HSP90 INHIBITORY PEPTIDE CONJUGATE AND APPLICATION THEREOF IN TREATING TUMOR

INSTITUTE OF BASIC MEDICA...

1. A conjugate, wherein the conjugate is a HSP90 inhibitory peptide conjugated to a cytotoxic agent via a linker,the HSP90 inhibitory peptide for inhibiting HSP90 expression having an amino acid sequence of LPLTPLP (SEQ ID No: 1),
the cytotoxic agent is selected from docetaxel, paclitaxel or doxorubicin, and
the linker has the following general formula: —CO—(CH2CH2)n—CO—, wherein n is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
US Pat. No. 10,918,732

GLYCOCONJUGATES AND METHODS FOR THEIR USE

THE BOARD OF REGENTS OF T...

1. A neoglycoconjugate comprising a trisaccharide coupled to a carrier, wherein the trisaccharide is Gal?(1,3)Gal?(1,4)Glc?, Gal?(1,2)Gal?(1,4)GlcNAc?, Gal?(1,2)Gal?(1,4)Glc?, or Gal?(1,2)Gal?(1,4)Glc?.
US Pat. No. 10,920,270

SPLIT-CYCLE AND TAPE AMPLIFICATION

Bio-Rad Laboratories, Inc...

1. A reaction mixture for performing a tagged amplicon primer extension (TAPE) nucleic acid amplification reaction, the mixture comprising:(i) a target DNA template molecule from a nucleic acid sample, wherein the target DNA template molecule comprises a target sequence;
(ii) a forward primer comprising:
(a) a 3? hybridization region of at least 10 nucleotides in length and no more than 30 nucleotides in length that is configured to specifically hybridize to the target sequence of the target DNA template molecule and generate a first primer extension product in the nucleic acid amplification reaction; and
(b) a 5? tail region of at least 10 nucleotides in length that is not complementary to the target sequence of the target DNA template molecule;
(iii) a reverse primer comprising:
(a) a 3? hybridization region of at least 10 nucleotides in length and no more than 30 nucleotides in length that is configured to specifically hybridize to the first primer extension product and generate a second primer extension product in in the nucleic acid amplification reaction; and
(b) a 5? tail region of at least 10 nucleotides in length that is not complementary to the target sequence of the target DNA template molecule, wherein the 5? tail region of the reverse primer is a reverse complement of the 5? tail region of the forward primer; and
(iv) a thermostable polymerase.
US Pat. No. 10,919,759

METHOD AND DEVICE FOR DETECTING CELLULAR TARGETS IN BODILY SOURCES USING CARBON NANOTUBE THIN FILM

UNIVERSITY OF LOUISVILLE ...

1. A device for detecting cellular targets comprising:a substrate;
a biofunctional pad comprising a thin film of carbon nanotubes (CNTs) disposed on said substrate and adapted to receive thereon antibodies associated with a cellular target,
wherein said thin film of CNTs has a free energy state associated therewith, and
wherein said biofunctional pad has at least one surface where the surface density of said CNTs along said at least one surface is lowered; and
a sensor, said sensor detecting changes in said free energy state when said antibodies attach to said thin film.
US Pat. No. 10,920,015

MEDIUM AND HIGH MOLECULAR WEIGHT LONG CHAIN ALIPHATIC NYLONS AND METHODS OF MAKING SAME

SHAKESPEARE COMPANY LLC, ...

1. A method of making aliphatic nylon polymers and/or copolymers, comprising,mixing at least one diamine with at least one diacid having 13 or more aliphatic carbon atoms to form a diamine-diacid salt solution;
removing a sample of the diamine-diacid salt solution and dissolving the sample of the diamine-diacid salt solution in a solvent comprising one or more C3 to C6 alcohols present in water in an amount of about 50% by volume, to form a dissolved diamine-diacid solution;
titrating the dissolved diamine-diacid solution to determine its balance point;
calculating the amount of diamine or diacid needed to bring the diamine-diacid salt solution to its balance point;
adding the calculated amount of diamine or diacid to the diamine-diacid salt solution to form a mixture; and
polymerizing the mixture to form a nylon polymer or copolymer,
wherein the nylon polymer or copolymer has a molecular weight greater than about 30,000 g/mol,
wherein the nylon polymer or copolymer comprises nylon 613, nylon 614, nylon 615, nylon 617, or nylon 618.
US Pat. No. 10,923,713

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

PANASONIC INTELLECTUAL PR...

1. A nonaqueous electrolyte secondary battery comprising a positive electrode, a negative electrode, and a nonaqueous electrolyte,wherein the positive electrode contains a lithium transition metal oxide, at least one element of a group 5 element and group 6 element in the periodic table, and a phosphoric acid compound represented by the general formula MxHyPO4 (M is a metal element, x is 1 to 2, and y is 1 to 2), a particle size of the phosphoric acid compound being within a range of 50 nm to 10 ?m and
the nonaqueous electrolyte contains a lithium salt containing a P—O bond and a P—F bond.
US Pat. No. 10,918,736

CONJUGATE OF THERAPEUTIC ENZYMES

HANMI PHARM. CO., LTD, H...

1. An enzyme conjugate, wherein a therapeutic enzyme for treating lysosomal storage disease (LSD) and an immunoglobulin Fc region are linked through a non-peptide polymer linkage moiety,wherein the non-peptide polymer linkage moiety is linked to the N-terminus of the immunoglobulin Fc region; and
wherein the enzyme conjugate has increased bioavailability (BA) compared to the enzyme to which the immunoglobulin Fc region is not linked.
US Pat. No. 10,921,297

ELUCIDATION OF ION EXCHANGE CHROMATOGRAPHY INPUT OPTIMIZATION

Genentech, Inc., South S...

1. A method for analyzing a composition comprising a polypeptide and one or more contaminants, wherein the method is a chromatography that effectively separates the polypeptide from the contaminants, the method comprisinga) binding the polypeptide and one or more contaminants to an ion-exchange chromatography material using a loading buffer, wherein the loading buffer comprises a buffer, and wherein a pH and temperature of the chromatography has been optimized for a plurality of target polypeptides; wherein the optimized pH for the plurality of target polypeptides is the pH at a common inflection point on a plot of net charge versus pH at a select temperature based on amino acid compositions of the target polypeptides; and wherein a pH of the buffer ranges from about 6.5 to about 8.5 at a temperature range of about 20° C. to about 70° C.;
b) eluting the polypeptide and one or more contaminants from the ion-exchange chromatography material using a gradient of an elution buffer, wherein the elution buffer comprises the buffer and a salt,wherein the polypeptide and the one or more contaminants are separated by the gradient; andc) detecting the polypeptide and the one or more contaminants.
US Pat. No. 10,918,737

METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER

Centre Hospitalier Univer...

1. A method of treating cancer in a subject in need thereof, comprisingco-administering to the subject a therapeutically effective amount of a combination of
an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an antibody inhibitor of programmed cell death protein-1 (PD-1) selected from the group consisting of nivolumab and pembrolizumab, with
a tumor necrosis factor-alpha (TNF?) blocking agent, wherein the TNF? blocking agent is an antibody having specificity for TNF? or TNF? receptor 1 (TNFR1) selected from the group consisting of certolizumab pegol, etanercept, infliximab, adalimumab, and golimumab,
wherein a dosing regimen of the therapeutically effective amount comprises at least one co-administration of at least 10 mg/kg of the immune checkpoint inhibitor and at least 10 mg/kg of the TNF? blocking agent,
wherein co-administration of the combination results in enhanced therapeutic efficacy relative to the administration of the immune checkpoint inhibitor alone,
wherein said cancer is selected from the group consisting of melanoma, breast cancer and lung cancer, and
wherein said therapeutic efficacy is indicated by regression of a tumor of the cancer.
US Pat. No. 10,920,274

NUCLEIC ACID COATED SUBMICRON PARTICLES FOR AUTHENTICATION

APDN (B.V.I.) Inc., Tort...

1. A method of attaching a nucleic acid to an object for authentication purposes comprising providing a plurality of submicron particles; adding an amount of nucleic acid suspended in a solvent to the submicron particles so that only enough nucleic acid is present to form a monolayer around each submicron particle; extracting the solvent to form a monolayer of nucleic acid covering each submicron particle; and attaching the nucleic acid covered submicron particles to an object to be authenticated using nucleic acid amplification and/or taggant sequence detection techniques for authentication.
US Pat. No. 10,918,738

METHOD OF TREATING TYPE I DIABETES USING AN AAV VECTOR ENCODING URACORTIN 2

THE REGENTS OF THE UNIVER...

1. A method for treating type 1 diabetes in a mammal comprising: injecting an adeno-associated viral vector (AAV) comprising a nucleic acid sequence encoding Uracortin 2 (UCN2) operably linked to a promoter to a mammal with type 1 diabetes intravenously (IV) such that increased insulin release and decreased hyperglycemia in the mammal occurs, thereby treating the type 1 diabetes in the mammal.
US Pat. No. 10,920,019

PREPARATION OF POLY AMIDOIMIDES

HUNTSMAN INTERNATIONAL LL...

1. A liquid composition comprising(a) a solvent or solvent mixture containing at least 50% by weight, based on the total amount of solvents, of a dioxabicycloalkane derivative,
(b) an aromatic tricarboxylic acid anhydride, and
(c) an aromatic diisocyanate.
US Pat. No. 10,920,275

METHODS FOR DIAGNOSIS OF TUBERCULOSIS

THE BOARD OF TRUSTEES OF ...

1. A method of treating a patient for tuberculosis, comprising:(a) identifying the patient as having tuberculosis based on the expression levels of GBP5, DUSP3 and KLF2 biomarkers in a biological sample from the patient; and
(b) administering an effective amount of at least one antibiotic to the patient.
US Pat. No. 10,920,276

GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF

Celera Corporation, San ...

6. A method for identifying a human as having an increased risk for psoriasis and alleviating the increased risk, the method comprising:a) testing nucleic acid from said human for a polymorphism rs11465804 in gene IL23R as represented by position 101 of SEQ ID NO:43 or its complement by contacting said nucleic acid with an allele-specific probe that specifically hybridizes to T at said position 101 of SEQ ID NO:43 or A at said complement;
b) detecting said T or said A; and
c) identifying said human as having an increased risk for psoriasis due to the presence of said T or said A; and
d) administering an anti-IL-12p40 antibody to said human.
US Pat. No. 10,918,740

RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES

1. A method of treating solid tumor in a patient in need thereof, the method comprising administering intratumorally to the tumor in the patient a pharmaceutically effective amount of a composition comprising an mRNA encoding IL-23 and having at least about 90% identity to wild-type mature human IL-23, wherein the mRNA encoding IL-23 is complexed with one or more lipids, thereby forming liposomes, lipid nanoparticles and/or lipoplexes.
US Pat. No. 10,920,277

COMPOSITIONS AND METHOD FOR TREATING COMPLEMENT-ASSOCIATED CONDITIONS

Genentech, Inc., South S...

1. A method of treating age-related macular degeneration (AMD) in a patient in need thereof comprising:(a) identifying a patient with AMD as more likely to respond to a therapy comprising an anti-factor D antibody, or antigen-binding fragment thereof comprising:
(i) detecting the presence of at least one AMD-associated polymorphism in a biological sample obtained from the patient, wherein the detecting comprises:
(1) providing a nucleic acid sample isolated from the biological sample; and
(2) detecting the genotype of the nucleic acid sample for the presence of at least one AMD-associated polymorphism, wherein at least one AMD-associated polymorphism is single nucleotide polymorphism (SNP) rs4698775; and
(ii) identifying the patient as more likely to respond to a therapy comprising anti-factor D antibody, or an antigen-binding fragment thereof, when at least one risk allele is present, wherein at least one risk allele comprises a G at SNP rs4698775; and
(b) treating the identified patient with AMD by administering an effective amount of a therapy comprising an anti-Factor D antibody, or an antigen-binding fragment thereof, to the identified patient.
US Pat. No. 10,920,022

METHOD FOR PRODUCING A PERMANENTLY COLORED OBJECT HAVING A SILICONE SURFACE AND COLORED OBJECT PRODUCED ACCORDING TO THE METHOD

1. A method for manufacturing a permanently colored cosmetic cover having a crosslinked silicone surface with a texturization in the form of creases, the cosmetic cover having the shape of a prosthesis, the method comprising:mixing color-conferring substances with a still crosslinkable silicone to form an application mixture;
solvent swelling the crosslinked silicone surface of the cosmetic cover;
applying the application mixture to the crosslinked silicone surface after the solvent swelling;
crosslinking the silicone of the application mixture as the application mixture penetrates into the crosslinked silicone surface to secure the application mixture to and permanently color the crosslinked silicone surface while leaving intact the creases of the crosslinked silicone surface.
US Pat. No. 10,920,023

MANUFACTURING METHOD OF SUPER ABSORBENT POLYMER AND SUPER ABSORBENT POLYMER

LG Chem, Ltd.

1. A manufacturing method for a super absorbent polymer, comprising:thermally polymerizing or photopolymerizing a monomer composition to form a hydrogel polymer, wherein the monomer composition including a water-soluble ethylenically unsaturated monomer and a polymerization initiator;
pulverizing the hydrogel polymer
to obtain a fine powder having a particle diameter of less than 150 ?m and a coarse-pulverized hydrogel polymer having a particle diameter of 2 to 20 mm;
mixing the fine powder, water, porous particles, and an additive to prepare a fine powder aqueous solution; and
manufacturing a fine powder reassembly by mixing the fine powder aqueous solution and the coarse-pulverized hydrogel polymer.
US Pat. No. 10,920,279

METHOD FOR MODIFYING A TREATMENT REGIMEN OF A HUMAN FEMALE SUBJECT

Genetic Technologies Limi...

1. A method for modifying a treatment regimen of a human female subject in accordance with the subject's risk of developing breast cancer, the method comprising:I) determining a genetic risk score of the human female subject by:
a) obtaining the identity of alleles present in the genome of the human female subject at at least 72 single nucleotide polymorphisms associated with breast cancer, of which at least 67 of the single nucleotide polymorphisms are selected from the group consisting of rs616488, rs11552449, rs11249433, rs6678914, rs4245739, rs12710696, rs4849887, rs2016394, rs1550623, rs1045485, rs13387042, rs16857609, rs6762644, rs4973768, rs12493607, rs9790517, rs6828523, rs10069690, rs10941679, rs10472076, rs1353747, rs1432679, rs11242675, rs204247, rs17529111, rs2046210, rs720475, rs9693444, rs6472903, rs2943559, rs13281615, rs11780156, rs1011970, rs10759243, rs865686, rs2380205, rs7072776, rs11814448, rs10995190, rs704010, rs7904519, rs2981579, rs11199914, rs3817198, rs3903072, rs554219, rs75915166, rs11820646, rs12422552, rs10771399, rs17356907, rs1292011, rs11571833, rs2236007, rs999737, rs2588809, rs941764, rs3803662, rs17817449, rs11075995, rs13329835, rs6504950, rs527616, rs1436904, rs8170, rs4808801, rs3760982, rs2823093, rs132390, and rs6001930, and the remaining single nucleotide polymorphisms are selected from the group consisting of rs616488, rs11552449, rs11249433, rs6678914, rs4245739, rs12710696, rs4849887, rs2016394, rs1550623, rs1045485, rs13387042, rs16857609, rs6762644, rs4973768, rs12493607, rs9790517, rs6828523, rs10069690, rs10941679, rs10472076, rs1353747, rs1432679, rs11242675, rs204247, rs17529111, rs2046210, rs720475, rs9693444, rs6472903, rs2943559, rs13281615, rs11780156, rs1011970, rs10759243, rs865686, rs2380205, rs7072776, rs11814448, rs10995190, rs704010, rs7904519, rs2981579, rs11199914, rs3817198, rs3903072, rs554219, rs75915166, rs11820646, rs12422552, rs10771399, rs17356907, rs1292011, rs11571833, rs2236007, rs999737, rs2588809, rs941764, rs3803662, rs17817449, rs11075995, rs13329835, rs6504950, rs527616, rs1436904, rs8170, rs4808801, rs3760982, rs2823093, rs132390, rs6001930, rs7696175, rs4415084, rs7726159, rs2736108, rs889312, rs2067980, rs2180341, rs9485370, RS12662670, rs3757318, rs17157903, rs10822013, rs2981582, rs614367, rs78540526, rs2363956, rs2284378, and rs17879961;
b) determining an adjusted risk score for each of the at least 72 SNPs, where:
(i) if two major alleles are present at the SNP, then the adjusted risk score for the SNP is 1/?,
(ii) if one major and one minor allele are present at the SNP, then the adjusted risk score for the SNP is OR/?,
(iii) if two minor alleles are present at the SNP, then the adjusted risk score for the SNP is OR2/?, and
(iv) if the genotype is missing for the SNP, then the adjusted risk score for the SNP is 1,
where ?=(1?p)2+2p(1?p)OR+p2OR2, wherein OR is the odds ratio of association with breast cancer of a minor allele at the given SNP and p is the frequency of the minor allele in the population to which the human female subject belongs; and
c) multiplying together the adjusted risk score for each of the at least 72 SNPs of the human female subject to produce a genetic risk score of the human female subject,
II) obtaining a clinical risk score of the human female subject,
III) multiplying the genetic risk score determined in step I by the human female subject's clinical risk score to obtain the human female subject's risk for developing breast cancer,
IV) administering a chemopreventative treatment appropriate for the risk of developing breast cancer determined in step III.
US Pat. No. 10,923,721

NEGATIVE ELECTRODE FOR A RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY COMPRISING SAME

Samsung SDI Co., Ltd., Y...

1. A negative electrode for a rechargeable lithium battery, the negative electrode consisting of:a current collector;
a layer of an active mass that includes a mixture of a negative active material and a binder, wherein:
the negative active material in the layer of the active mass has a Young's modulus of about 10 GPa to about 35 GPa,
the layer of the active mass has an active mass density of about 1.65 g/cc to about 1.85 g/cc, the active mass density indicating weight of the active mass divided by volume of the negative electrode, and
the negative electrode exhibits a current density of greater than or equal to about 3.2 mAh/cm2.
US Pat. No. 10,919,000

MXENE BASED COMPOSITING NANOFILTRATION MEMBRANE AND CORRESPONDING PREPARATION METHOD

Dalian University of Tech...

1. An MXene based composite nanofiltration membrane, wherein the composite nanofiltration membrane is a flat structure, comprising a supporting layer below a separation functional layer;the functional layer is a dense thin membrane made of the MXene and a crosslinking agent below 50 ?m;
the crosslinking agent is glutaraldehyde, epoxy chloropropane, epoxy propyl trimethylammonium chloride, trimesoyl chloride, phthaloyl chloride, isophthaloyl dichloride, paraphthaloyl chloride, or hexanedioyl chloride;
the supporting layer is made of cellulose derivative, polysulfone, polyether sulfone, polyethylene sulfone, polyacrylonitrile, polyvinyl chloride, polyvinylidene chloride, polyimide, polyetherimide, or a combination thereof; a thickness of the supporting layer is between 50-500 ?m with pores about 100 nm.
US Pat. No. 10,920,025

POLYOLEFIN RESIN POWDER SUITABLE FOR SELECTIVE LASER SINTERING AND ITS PREPARATION METHOD

1. A method for preparing a polyolefin resin powder, comprising:a) heating and dissolving a polyolefin resin in an organic solvent having a solubility parameter less than or equal to a solubility parameter of the polyolefin resin to obtain a polyolefin resin solution;
b) cooling the polyolefin resin solution to cause precipitation of a solid, thereby obtaining a solid-liquid mixture;
c) optionally adding an adjuvant to the solid-liquid mixture; and
d) conducting solid-liquid separation and drying the separated solid to obtain a polyolefin resin powder,
wherein a difference between the solubility parameter of the organic solvent and the solubility parameter of the polyolefin resin is within 0-20% of the solubility parameter of the polyolefin resin,
wherein, in the polyolefin resin solution, an amount of the organic solvent is 600-1200 parts by weight, based on an amount of 100 parts by weight of the polyolefin resin,
wherein, in step b), the polyolefin resin solution is cooled to a target temperature via one or more intermediate temperatures and held for 30-90 minutes at each of said one or more intermediate temperatures,
wherein the one or more intermediate temperatures are in the range of 40-100° C., and
wherein the polyolefin resin powder obtained from step d) contains particles that are spherical or spheroidal particles having a particle size of 25-150 ?m, and a particle size distribution D10=43-69 ?m, D50=61-103 ?m, and D90=85-138 ?m.
US Pat. No. 10,920,281

RASAL1 IS A MAJOR TUMOR SUPPRESSOR GENE IN THYROID CANCER

The Johns Hopkins Univers...

1. A method for predicting an increased risk of thyroid cancer in a human patient comprising the steps of:(a) treating DNA isolated from a sample comprising thyroid cells collected from the patient using bisulfite;
(b) measuring the DNA methylation level of the promoter region of the RASAL1 gene from the bisulfite-treated DNA using methylation-specific polymerase chain reaction (MSP), wherein gel electrophoresis of the MSP amplification products creates a methylation and unmethylation band, wherein the MSP is performed using the methylation-specific primers shown in SEQ ID NOS:35-36;
(c) normalizing the measured DNA methylation level using an internal reference gene;
(d) calculating the percentage of allelic methylation using the formula [M/(M+U]×100%, wherein M and U represent the density of the methylation and unmethylation band; and
(e) predicting an increased risk of thyroid cancer in the patient if the percentage of allelic methylation is at least 50%.
US Pat. No. 10,920,026

POLYMER COMPOSITION, MOLDED PART AND PROCESSES FOR PRODUCTION THEREOF

DSM IP ASSETS B.V., Heer...

1. A reinforced thermoplastic polymer composition consisting of:(A) a polymer comprising 30-90 wt. %, based on total weight of the polymer (A), of at least a first semi-crystalline semi-aromatic polyamide (SSPA-1) having a melting temperature (Tm) of at least 300° C.;
(B) 10-70 wt. % of at least one reinforcing agent, and
(C) 0-25 wt. % of one or more other components, wherein the SSPA-1 consists of:
(A-1-a) 90-100 mole % of repeat units derived from (i) aromatic dicarboxylic acid and (ii) diamines, and
(A-1-b) 0-10 mole % of repeat units derived from other monomers; wherein
the diamines (ii) consist of 80-95 mole % of linear aliphatic diamine, 5-20 mole % of 2-methyl-pentamethylene diamine, and 0-10 mole % of other diamines; and wherein
the mole percentages (mole %) of the linear aliphatic diamine, the 2-methyl-pentamethylene diamine and the other diamines are relative to the total molar amount of the diamines (ii);
the mole % of (A-1-a) and (A-1-b) are relative to the total molar amount of monomeric repeat units (A-1-a) and (A1-b) in the SSPA-1;
the weight percentages (wt. %) of the components (A), (B) and (C) are relative to the total weight of the composition, with the sum of the components (A), (B) and (C) being 100 wt. %.
US Pat. No. 10,920,282

PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD

TORAY INDUSTRIES, INC., ...

1. A method for detecting pancreatic cancer, comprising: measuring an expression level of hsa-miR-4294 in a sample comprising blood, serum, or plasma from a human subject using a kit comprising a nucleic acid(s), as a primer(s) or a probe(s), capable of specifically binding to hsa-miR-4294, wherein the measuring comprises the following steps of:(a) contacting hsa-miR-4294 in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-4294 with the nucleic acid(s);
(b) measuring an expression level of hsa-miR-4294 using the nucleic acid(s) as the primer(s), or using the nucleic acids as the probe(s); and
(c) comparing the expression level of hsa-miR-4294 measured in the step (b) with a control expression level of hsa-miR-4294 in a control sample from a healthy subject measured in the same way as in the step (b),
wherein a lower expression level of hsa-miR-4294 in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has pancreatic cancer; and
treating the subject for pancreatic cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof, and wherein the diagnostic procedure comprises abdominal ultrasonography, CT scanning, endoscopic retrograde cholangiopancreatography, or endoscopic ultrasonography, or a combination thereof.
US Pat. No. 10,920,283

METHODS TO ESTABLISH AND RESTORE NORMAL GUT MICROBIOTA FUNCTION OF SUBJECT IN NEED THEREOF

1. A method to determine the relative maturity of a subject's gut microbiota to identify and treat a subject in need of treatment, the method comprising:(a) detecting a relative abundance for each bacterial taxon in a group comprising (i) obtaining a fecal sample from a subject or providing a fecal sample obtained from a subject; (ii) isolating nucleic acids from the fecal sample; (iii) amplifying nucleic acids with primers directed at a variable region of a bacterial 16S rRNA gene; and (iv) detecting nucleic acids associated with bacterial taxa in the group by 16S rRNA sequencing or hybridization array; wherein the group comprises Faecalibacterium prausnitzii OTU ID 326792, Ruminococcus sp. 5 1 39BFAA OTU ID 189827, Lactobacillus ruminis OTU ID 470663, Dorea longicatena OTU ID 191687, Bifidobacterium longum OTU ID 72820, and Ruminococcus sp. 5 1 39BFAA OTU ID 194745;
(b) determining a microbiota age for the subject's gut microbiota comprising applying the relative abundances of the bacterial taxa from step (a) to a regression model, wherein the model regresses, for a group of healthy subjects, relative abundances of the same bacterial taxa, as determined from a plurality of gut microbiota samples obtained over time for each healthy subject in the group, against the chronological age of each healthy subject in the group at the time the gut microbiota sample was obtained;
(c) calculating the relative maturity of the subject's gut microbiota, wherein relative maturity=(microbiota age of the subject)?(microbiota age of a healthy subject of a similar chronological age); and
(d) providing a treatment to the subject with a relative maturity that is a negative value to increase the relative maturity value.
US Pat. No. 10,920,284

PATHOGEN AND ANTIMICROBIAL RESISTANCE TESTING

Labrador Diagnostics LLC,...

1. An insertable cartridge for being received in a slot of a sample analysis device for analysis of a sample, said cartridge comprising:at least one pipette tip;
a plurality of vessels;
a support frame with openings for holding said vessels and said at least one pipette tip;
at least a first of said vessels containing an antimicrobial;
at least a second of said vessels containing a microorganism growth medium;
at least a third of said vessels containing at least one reagent selected from the group consisting of: a metabolic indicator, a reagent for a nucleic acid amplification reaction, and a reagent for a nucleic acid probe-based assay;
at least a first opening for holding a first type of sample vessel; and
at least a second opening for holding a second type of sample vessel different from the first type of sample vessel;
wherein at least one of said vessels is detachable from the support frame;
a microscopy cuvette coupled to said support frame;
a cap-removal tip coupled to said support frame; and
reagent in said vessels to support at least another type of assay different from nucleic acid amplification, said another type of assay selected from the following: metabolic/biochemical assay, immunoassay, or cytometry;
wherein said support frame is configured to engage a matching slot at a cartridge receiving location in the sample processing device, and wherein the cartridge is ejectable from the sample processing device after assay processing.
US Pat. No. 10,920,029

POLYETHYLENE AND CYCLIC OLEFIN COPOLYMER BLEND COMPOSITIONS WITH OXYGEN BARRIER PROPERTIES AND ARTICLES MADE THEREFROM

ExxonMobil Chemical Paten...

1. A monolayer, sealable film, comprising:polyethylene; and
about 0.2 wt % to about 10 wt % of a branched cyclic olefin copolymer, bCOC, comprising:
about 50 wt % to about 98 wt % ethylene derived monomer units; and
about 2 wt % and about 50 wt % cyclic olefin derived monomer units.
US Pat. No. 10,920,285

HIGHLY SPECIFIC AND SENSITIVE METHODS FOR DETECTING ENTEROHEMORRHAGIC ESCHERICHIA COLI SEROTYPES O157:H7 AND/OR O145:H28

QIAGEN GMBH, Hilden (DE)...

1. A method of detecting E. coli serotype O157:H7 in a sample, the method comprising:(a) obtaining a sample;
(b) detecting whether E. coli serotype O157:H7 is present in the sample by performing an amplification reaction using at least one oligonucleotide as an amplification primer, wherein the oligonucleotide has a nucleotide sequence that is at least 90% identical to a nucleotide sequence of the same length within SEQ ID NO: 10 or to the complement of the nucleotide sequence of the same length, and wherein the oligonucleotide further comprises: (i) nucleotides 382-385 of SEQ ID NO: 10 or the complement thereof, (ii) nucleotides 382-384 of SEQ ID NO: 10 or the complement thereof, or (iii) nucleotides 383-385 of SEQ ID NO: 10 or the complement thereof, and wherein the oligonucleotide has a length of about 10-100, about 10-50 nucleotides, about 10-30 nucleotides, or 18-27 nucleotides; and
(c) determining the presence of a E. coli serotype O157:H7 in the sample.
US Pat. No. 10,920,030

PREPREG, METHOD FOR ITS PRODUCTION, AND FIBER-REINFORCED MOLDED PRODUCT

AGC Inc., Chiyoda-ku (JP...

1. A prepreg comprising reinforcing fibers and a matrix resin, wherein the matrix resin comprises a thermoplastic resin (but excluding the following fluororesin) and a melt-moldable fluororesin having functional groups of at least one type selected from the group consisting of carbonyl group-containing groups, hydroxy groups, epoxy groups and isocyanate groups, wherein the matrix resin has a sea-island structure composed of a sea portion containing the thermoplastic resin and island portions containing the fluororesin, wherein the average diameter of the island portions is from 0.01 to 200 ?m, and in 100 mass % of the total of the thermoplastic resin and the fluororesin, the proportion of the thermoplastic resin is from more than 30 to 99 mass % and the proportion of the fluororesin is from 1 to less than 70 mass %.
US Pat. No. 10,920,286

PLANTS WITH USEFUL TRAITS AND RELATED METHODS

NUTECH VENTURES, Lincoln...

1. A method for producing a plant exhibiting improved yield comprising the steps of:a. suppressing expression of endogenous MSH1 gene(s) in a plant or plant cell by a genetic manipulation effected with:
(i) a transgene comprising an MSH1 gene or MSH1 gene fragment of at least 18 to about 500 or more nucleotides that suppresses expression of the endogenous MSH1 gene(s),
(ii) a mutation in the endogenous MSH1 gene, or
(iii) a nucleic acid comprising an MSH1 gene or MSH1 gene fragment of at least 18 to about 500 or more nucleotides that suppresses expression of the endogenous MSH1 gene(s) to obtain a first parental plant;
b. crossing the first parental plant to a second parental plant;
c. recovering F1 progeny plants or an F1 progeny plant line from the cross of the first parental plant of step (b) wherein MSH1 function is restored;and,d. selecting an F1 progeny plant or an F1 progeny plant line from a recovered F1 progeny plant or F1 plant line of step (c), wherein the selected F1 progeny plant or selected F1 plant line exhibits improved yield in comparison to a control plant, wherein said improved yield is associated with one or more epigenetic changes in the nucleus of the F1 progeny plant cells relative to the corresponding parental chromosomal loci and is heritable.
US Pat. No. 10,919,775

METHOD FOR PREPARING LITHIUM CARBONATE FROM LITHIUM IRON PHOSPHATE BATTERY SCRAPS AND LITHIUM CARBONATE THEREOF

1. A method for preparing lithium carbonate from lithium iron phosphate battery scraps, comprising: performing oxidative acidolysis on a lithium iron phosphate material, improving concentration of lithium in a lithium-containing solution output from the step of performing oxidative acidolysis, adding alkali to remove iron, and precipitating lithium carbonate, thereby obtaining a filter cake which is a lithium carbonate product, wherein the step of improving concentration of lithium in the lithium-containing solution comprises:adding a first acid liquor into the lithium-containing solution repeatedly until the concentration of lithium reaches a desired value, wherein the first acid liquor is a concentrated acid liquor, and times to repeat the step of improving concentration of lithium in the lithium-containing solution include at least 2-6 times.
US Pat. No. 10,920,031

PREPREG AND FIBER-REINFORCED COMPOSITE MATERIAL

Mitsubishi Chemical Corpo...

12. A fiber-reinforced composite material comprising:(A) a reinforced fiber substrate;
(B?) a cured material of an epoxy resin composition comprising an epoxy resin component and a curing agent component; and
(C) a component (c1) comprising spherical polyamide particles having an average particle diameter of 2 to 50 ?m and thermosetting polyimide particles having an average particle diameter of 2 to 50 ?m, provided that the average particle diameter of the thermosetting polyimide particles is 0.5 to 10 times the average particle diameter of the spherical polyamide particles,
wherein the epoxy resin composition comprises 5 to 70 mass % of an epoxy resin having an oxazolidone ring structure or 60 to 100 mass % of an epoxy resin having a naphthalene structure, with respect to 100 mass % of the entire epoxy resin in (B),
wherein the curing agent component is an aromatic polyamine when the epoxy resin composition comprises 60 to 100 mass % of an epoxy resin having a naphthalene structure, with respect to 100 mass % of the entire epoxy resin in (B),
wherein (B) and (C) together, account for 25 to 50 mass % of the prepreg,
a plurality of the component (A) are laminated, and
the component (C) is present between layers of the components (A).
US Pat. No. 10,920,287

COMPOSITION AND METHOD FOR IMAGING STEM CELLS

Global Life Sciences Solu...

1. A method for monitoring differentiation status of a stem cell, comprising:delivering to the stem cell a plasmid expression vector comprising:
a first reporter nucleic acid sequence encoding a human renilla luciferase (hRLUC) polypeptide, operably linked to an Oct4 promoter;
a second reporter nucleic acid sequence encoding a polypeptide selected from a green fluorescence protein (GFP), a red fluorescence protein (RFP), or a thymidine kinase (TK), operably linked to a second expression control sequence comprising a minimal promoter and a response element, wherein the response element comprises at least four repeats of GATA-4 protein-binding sequence, and wherein the response element is responsive to binding of one or more response element specific protein GATA4; and
a third reporter nucleic acid sequence encoding a double fusion polypeptide of a firefly luciferase and a green fluorescence protein (FLUC2-eGFP), operably linked to an ubiquitin promoter; and
monitoring the stem cell by imaging an expression of the third reporter nucleic acid sequence, and at least one of the first reporter nucleic acid sequence and the second reporter nucleic acid sequence.
US Pat. No. 10,921,311

FUSIONS AND METHOD FOR DETECTING SAME

JAPANESE FOUNDATION FOR C...

1. A kit for detecting a PXN-BRAF fusion gene in a sample obtained from a subject, the kit comprising sense and antisense primers designed to be capable of specifically amplifying a polynucleotide encoding a polypeptide which is a fusion protein of the PXN protein with the BRAF protein,wherein the sense primer consists of an oligonucleotide of at least 16 consecutive nucleotides arbitrarily selected from nucleotide positions 1 to 962 of SEQ ID NO: 1, and the antisense primer consists of an oligonucleotide complementary to an oligonucleotide of at least 16 consecutive nucleotides arbitrarily selected from nucleotide positions 963 to 2067 of SEQ ID NO: 1.
US Pat. No. 10,919,007

ORGANIC MATERIAL PURIFICATION COMPOSITION AND METHOD OF PURIFYING ORGANIC MATERIALS USING THE SAME

Samsung Display Co., Ltd....

1. An organic material purification composition, comprising: an ionic liquid in which a cation and an anion are combined; and an organic solvent, wherein the organic solvent includes an alcohol or a ketone,wherein the alcohol includes ethanol, propanol, or butanol.
US Pat. No. 10,920,032

LIGHT-BLOCKING ARTICLES WITH SPACER FUNCTIONAL COMPOSITION

EASTMAN KODAK COMPANY, R...

1. A foamed, opacifying element comprising:a substrate having a first opposing surface and a second opposing surface;
a foamed opacifying layer disposed on the first opposing surface of the substrate, and
a functional composition that is non-foamed and is disposed over the foamed opacifying layer, the non-foamed functional composition forming a non-foamed functional layer that is the outermost layer in the foamed, opacifying element, and comprising (i) glass particles;
wherein the foamed opacifying layer comprises:
(a) at least 0.1 weight % and up to and including 40 weight % of porous particles, each porous particle comprising a continuous polymeric phase and discrete pores dispersed within the continuous polymeric phase, the porous particles having a mode particle size of at least 2 ?m and up to and including 50 ?m;
(b?) at least 10 weight % and up to and including 80 weight % of a matrix material that is derived from a (b) binder material having a glass transition temperature (Tg) of less than 25° C.;
(c) at least 0.0001 weight % and up to and including 50 weight % of one or more additives selected from the group consisting of dispersants, foaming agents, foam stabilizing agents, plasticizers, flame retardants, optical brighteners, thickeners, biocides, tinting colorants, metal particles, and inert inorganic or organic fillers;
(d) less than 5 weight % of water; and
(e) at least 0.002 weight % of an opacifying colorant different from all of the one or more additives of (c), which opacifying colorant absorbs electromagnetic radiation having a wavelength of at least 380 nm and up to and including 800 nm,
all amounts being based on the total weight of the foamed opacifying layer.
US Pat. No. 10,921,312

GANGLIOSIDES FOR STANDARDIZING AND INCREASING THE SENSITIVITY OF CELLS TO BOTULINUM NEUROTOXINS IN IN VITRO TEST SYSTEMS

1. A method for standardizing the sensitivity of induced pluripotent stem cell (iPS)-derived neurons to a neurotoxin polypeptide, comprising the steps of:a) measuring the sensitivity of neurons from different batches of induced pluripotent stem cell-derived neurons to a neurotoxin polypeptide to establish variability in sensitivity across the different batches;
b) cultivating neurons from said different batches of induced pluripotent stem cell-derived neurons in a cell culture medium comprising GT1b for at least 3 hours;
c) contacting the neurons of step b) with a neurotoxin polypeptide;
d) cultivating neurons of step c) for at least 24 hours in the presence of GT1b under conditions which allow for the neurotoxin polypeptide to exert its biological activity;
e) measuring the sensitivity of the different batches of induced pluripotent stem cell-derived neurons to a neurotoxin polypeptide in step d) to establish a reduction in variability in sensitivity across the different batches relative to the variability in sensitivity across the different batches in step a).
US Pat. No. 10,920,033

EXPANDABLE VINYL AROMATIC COMPOSITION CONTAINING FUNCTIONALIZED ETHYLENE-VINYL ACETATE COPOLYMER

Versalis S.P.A., San Don...

1. Expandable polymeric composition comprising:a) from 70% to 90% by weight of a vinyl aromatic polymer and/or vinyl aromatic copolymer, calculated with respect to (a)+(b);
b) from 10% to 30% by weight of an ethylene-vinyl acetate copolymer (EVA) containing a percentage that ranges from 10% to 30% by weight of vinyl acetate, calculated with respect to (a)+(b);
c) from 3 to 10 parts by weight of a blowing agent, calculated on 100 parts of component a) added to component b);said ethylene-vinyl acetate copolymer (EVA) being distributed in said vinyl aromatic polymer and/or said vinyl aromatic copolymer in the form of particles having an average volumetric diameter ranging from 1 nm to 2000 nm; and with the proviso that said expandable polymeric composition does not contain a hydrogenated or non-hydrogenated, styrene-butadiene or styrene-isoprene block copolymer, a thermoplastic polyurethane, a polystyrene-butadiene grafted polymer or a styrene core-shell polymer.
US Pat. No. 10,920,289

METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIES

Ovik Leonardovich Mkrtchy...

1. A method for the detection of viruses with lymphotropism properties in biological material with a low virus concentration, comprising:sampling a biological material from a patient;
forming an admixture of an equal amount of said biological material from said patient with a lymphocyte suspension from a healthy human subject;
incubating the admixture;
washing-out the lymphocytes in the admixture;
concentrating lymphocyte cytoplasm content within said admixture by removing lymphocyte membranes from the admixture; and
detecting, within said lymphocyte cytoplasm content, the presence or absence of the virus RNA or DNA,
wherein the presence of the virus RNA or DNA in the lymphocyte cytoplasm content, with an earlier non-detection of infection, indicates the preserved viability of viruses in said biological sample of said patient,
wherein the absence of the virus RNA or in the lymphocyte cytoplasm content indicates the loss of virus viability in said biological sample of said patient.
US Pat. No. 10,921,313

POINT OF CARE TESTING ASSAY SYSTEM USING NOVEL MICROFLUIDICS

micobiomed., Ltd, Seongn...

1. A point of care testing assay system comprising:a microfluidic testing cartridge comprising:
a single row of chambers comprising:
a first chamber for storing a sample;
a second chamber including lyophilized detection antibody;
a mixing chamber; and
a plurality of detection chambers,
a reagent pack including buffers and substrate; and
a precision pipettor configured to:
transfer the buffers from the reagent pack to the second chamber to reconstruct the detection antibody;
aspirate a sample in the first chamber and dispense the aspirated sample to the mixing chamber;
aspirate the reconstructed detection antibody in the second chamber and dispense the aspirated reconstructed detection antibody to the mixing chamber; and
aspirate the mixture of the sample and reconstructed detection antibody in the mixing chamber and dispense the aspirated mixture to the plurality of detection chambers
a detection module configured to detect luminescence of the plurality of detection chambers;
a horizontal motion stage configured to move the microfluidic testing cartridge; and
a vertical motion stage configured to move the precision pipettor or the detection module,
wherein each of the plurality of detection chambers includes a single well and a single microfluidic channel connected below the single well,
one or more of the plurality of detection chambers is pre-coated with capture antibodies,
top surfaces of the first chamber, the second chamber, the mixing chamber, and the plurality of detection chambers are circularly shaped, equally sized, and linearly arranged on the microfluidic testing cartridge, and
wherein the microfluidic channel is formed in a spiral pattern and a central portion of each microfluidic channel is connected to a bottom portion of each well.
US Pat. No. 10,918,753

USE OF OZONE TO CONTROL BIOBURDEN IN PRECIPITATED CALCIUM CARBONATE SLURRY (PCC)

Colgate-Palmolive Company...

1. A method for reducing bacteria in a precipitated calcium carbonate (CaCO3) slurry, the method comprising:adding water to calcium oxide (CaO) to form Ca(OH)2;
treating the Ca(OH)2 with CO2 gas to form a slurry comprising precipitated CaCO3;
neutralizing the slurry; and
exposing the slurry that was neutralized to ozone in an amount sufficient to reduce bacteria in the precipitated calcium carbonate slurry,
wherein a solid concentration of precipitated CaCO3 in the slurry ranges from about 12% w/w to about 40% w/w;
wherein the concentration of ozone in the neutralized slurry ranges from about 5 ppm to about 25 ppm.
US Pat. No. 10,920,034

RESIN COMPOSITION AND USE THEREOF

SUMITOMO CHEMICAL COMPANY...

1. A resin composition comprising:a crosslinked polymer (1) whose enthalpy of fusion observed within a temperature range of 10° C. or higher and lower than 60° C. in differential scanning calorimetry is 30 J/g or more;
a polymer (2) whose melting peak temperature or glass transition temperature observed in differential scanning calorimetry is 50° C. or higher and 180° C. or lower, provided that the polymer (2) is different from the polymer (1), and
a thermally conductive material (3) whose thermal conductivity is 1 W/(m·K) or higher, wherein
a content of the crosslinked polymer (1) is 30 wt % or more and 99 wt % or less and a content of the polymer (2) is 1 wt % or more and 70 wt % or less, with respect to 100 wt % of the total amount of the crosslinked polymer (1) and the polymer (2) and
a content of the thermally conductive material (3) is 5 parts by weight or more and 80 parts by weight or less, with respect to 100 parts by weight of the total amount of polymer components contained in the resin composition.
US Pat. No. 10,920,290

ENGINEERED BACTERIAL STRAIN THAT REDUCES ANTIBIOTIC-RESISTANT ENTEROCOCCUS COLONIZATION IN THE GI TRACT

The Medical College of Wi...

1. A modified Enterococcal strain, wherein the strain comprises:a. a ?srtA mutation,
b. a first plasmid encoding Bac 21, wherein the plasmid has a ?bacAB mutation, and
c. a second plasmid encoding a proximal part of bac-21 operon.
US Pat. No. 10,919,266

METHOD FOR PROTECTION FROM EXPLOSION AND FIRE

1. A method for extinguishing a fire which comprises:providing at least one container filled with fire extinguishing chemicals;
providing an explosive proximate to the container,
whereby the fire extinguishing chemicals are propelled by the blast energy of the explosion to extinguish the fire
and
wherein the step of providing an explosive proximate to the container further includes the step of covering the explosive with an anti-explosive blanket that in response to heat will decompose to absorb the energy of fire and heat and extinguish the fire.
US Pat. No. 10,921,315

RECOMBINANT DEAMIDATED GLIADIN ANTIGEN

Bio-Rad Laboratories, Inc...

1. A method of diagnosing celiac disease in a subject, the method comprising:(a) contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein consisting of SEQ ID NO:7 or SEQ ID NO:8; and
(b) detecting an antibody from the sample that specifically binds to the recombinant or synthetic deamidated gliadin protein, thereby diagnosing celiac disease in the subject.
US Pat. No. 10,923,732

METHOD FOR PRODUCING ROLL-TYPE GAS DIFFUSION LAYER HAVING EXCELLENT SPREADING PROPERTY

KOLON INDUSTRIES, INC., ...

1. A method for producing a roll of gas diffusion layer sheet, comprising:(i) performing heat treatment on a cellulose fiber as a carbon fiber precursor at a temperature of 1,750 to 2,450° C. to prepare a carbon fiber having a strength of 0.5 to 1.2 Gpa and a modulus of 10 to 100 Gpa;
(ii) cutting the prepared carbon fiber in a length of 3 to 56 mm to prepare carbon fiber chops, and then introducing the carbon fiber chops into a paper pulp-manufacturing apparatus along with a binder fiber, a surfactant, a thickener, and an anti-foaming agent, so as to prepare a carbon paper sheet;
(iii) impregnating the prepared carbon paper sheet with a resin, carbonizing the resin-impregnated carbon paper sheet at 1,800 to 2,400° C., and forming a microporous polytetrafluoroethylene resin layer on one surface of the carbonized carbon paper, so as to prepare a gas diffusion layer sheet; and
(iv) winding the prepared gas diffusion layer sheet on a roll to give the roll of gas diffusion layer sheet,
wherein the carbon fiber has a diameter of 6 to 10 ?m, an electrical resistivity of 0.0001 to 0.9 ?·cm, and a density of 1.4 to 1.5 g/cm3, and
wherein the carbon paper sheet produced in (ii) has a weight of 15 to 100 g/m2.
US Pat. No. 10,919,011

POWDER MIXING APPARATUS AND METHOD OF USE

Adamis Pharmaceuticals Co...

1. A method of mixing a powder, the method comprising: providing a first premixed powder to a first powder input portion, the first powder input portion comprising a first dispensing device; mixing the first premixed powder in a first mixing portion, the first mixing portion comprising a first powder inlet, a first gas inlet, and a first mixing cavity; wherein the first dispensing device comprises a venturi tube configured to dispense the first premixed powder into the first mixing portion; wherein the first gas inlet is configured to provide a first flow of gas into the first mixing cavity, and the first powder inlet is configured to dispense the first premixed powder into the first mixing cavity; and wherein the first flow of gas and the first premixed powder interact in the first mixing cavity to form a first post-mixed powder, and further comprising providing the first post-mixed powder to a second powder input portion, the second powder input portion comprising a second dispensing device; mixing the first post-mixed powder in a second mixing portion, the second mixing portion comprising a second powder inlet, a second gas inlet, and a second mixing cavity; wherein the second dispensing device comprises a second opening configured to dispense the first post-mixed powder into the second mixing portion; wherein the second pas inlet is configured to provide a second flow of gas into the second mixing cavity, and the second powder inlet is configured to dispense the first post-mixed powder into the second mixing cavity; and wherein the second flow of gas and the first post-mixed powder interact in the second mixing cavity to form a second post-mixed powder.
US Pat. No. 10,919,267

CONTACT LAYER WITH MINERAL BINDER COMPONENT

SIKA TECHNOLOGY AG, Baar...

1. A contact layer comprising a mineral binder component B, a thermoplastic polymer component P and a surfactant component S,wherein the amount of the mineral binder component B is in a range of 10.0 to 90.0 wt.-% based on the total weight of the contact layer,
the thermoplastic polymer component P comprises at least one polymer selected from the group consisting of ethylene-vinyl acetate co-polymers (EVA), ethylene-acrylic ester copolymers, ethylene-?-olefin co-polymers, ethylene-propylene co-polymers polypropylene (PP), polyethylene (PE), polyvinylchloride (PVC), polyethylene terephthalate (PET), polystyrene (PS), polyamides (PA), chlorosulfonated polyethylene (CSPE), ethylene propylene diene rubber (EPDM), and polyisobutylene (PIB),
the contact layer is formed by extruding a homogenized melt comprising the mineral binder component B, the thermoplastic polymer component P, and the surfactant component S through a manifold or a flat die followed by cooling the extruded material between calendar cooling rolls, the homogenized melt being formed by melt-processing a composition comprising the mineral binder component B, the thermoplastic polymer component P, and the surfactant component S at a temperature, which is above the melting point of point of the thermoplastic polymer component P, and
the amount of water in the homogenized melt is less than 1.0 wt.-%.
US Pat. No. 10,920,036

VULCANIZABLE COMPOSITIONS BASED ON HYDROGENATED NITRILE RUBBER, METHOD FOR PRODUCING SAME, AND USE THEREOF

ARLANXEO DEUTSCHLAND GMBH...

1. A vulcanizable composition comprising:(a) at least one hydrogenated nitrile rubber,
(b) least one mineral filler which comprises calcined kaolin with specific surface area (N2 surface area) smaller than 10 m2/g comprising at least 40% by weight silicate (SiO2) and at least 10% by weight aluminium oxide (AI2O3) based on the total amount of component (b),
(c) at least one basic sodium silicate, and
(d) at least one peroxide compound.
US Pat. No. 10,918,756

SOLID NON-AQUEOUS GEL AIR ODORIZER

Dow Global technologies L...

1. A solid non-aqueous gel air odorizer, comprising:20 to 75 wt %, based on weight of the solid non-aqueous gel air odorizer, of a poly(propylene oxide); wherein the poly(propylene oxide) has a weight average molecular weight of 300 to 1,000 Daltons;
0.5 to 30 wt %, based on weight of the solid non-aqueous gel air odorizer, of an ethyl cellulose polymer;
20 to 75 wt %, based on weight of the solid non-aqueous gel air odorizer, of a C1-5 alkyl monoester of a C8-22 fatty acid; and
4.5 to 50 wt %, based on weight of the solid non-aqueous gel air odorizer, of a fragrance;
wherein the solid non-aqueous gel air odorizer contains <1.5 wt %, based on weight of the solid non-aqueous gel air odorizer, water.
US Pat. No. 10,919,012

CRUDE OIL DISPERSION STABILIZER

KURARAY CO., LTD., Kuras...

1. A crude oil dispersion liquid, comprising:a crude oil treatment agent and a crude oil,
wherein the crude oil treatment agent comprises a crude oil dispersion stabilizer and water, and comprises 0.05 to 40 parts by mass of the crude oil dispersion stabilizer relative to 100 parts by mass of an entire amount of the crude oil treatment agent, wherein the crude oil dispersion stabilizer comprises a vinyl alcohol-based polymer, wherein a degree of saponification of the vinyl alcohol-based polymer is greater than 70 mol % and 82 mol % or less, and a total content of carboxyl groups and lactone rings is 0.02 to 1 mol % relative to all structural units of the vinyl alcohol-based polymer, and
the crude oil dispersion liquid comprises 3 to 50 parts by mass of the crude oil treatment agent, 0.001 to 1 part by mass of the vinyl alcohol-based polymer, and 50 to 97 parts by mass of the crude oil, relative to 100 parts by mass of an entire amount of the crude oil dispersion liquid.
US Pat. No. 10,920,037

THERMALLY CONDUCTIVE POLYMER RESIN COMPOSITION BASED ON STYRENICS WITH LOW DENSITY

INEOS STYROLUTION GROUP G...

1. A thermally conductive polymer (TCP) resin composition comprising components (X) and (Y):90 to 99.9% by weight of component (X) which is a composition comprising components (I) and (II):
60 to 85% by volume of at least one matrix polymer (I) as component (I) comprising styrenic polymers (I?) selected from the group consisting of: ABS (acrylonitrile-butadiene-styrene) resins, ASA (acrylonitrile-styrene-acrylate) resins, and elastomeric block copolymers; wherein the elastomeric block copolymers have a structure
(S—(B/S))n—S,
where S is a vinylaromatic block forming a hard phase, (B/S) is a random copolymer block of vinylaromatic monomer and of a conjugated diene forming a soft phase, and n are natural numbers from 1 to 10, wherein the elastomeric block copolymer has a monomer composition comprising from 25 to 60% by weight (based on the elastomeric block copolymer) of diene and from 75 to 40% by weight (based on the elastomeric block copolymer) of vinylaromatic compound, the glass transition temperature Tg of block S is above 25° C. and that of block (B/S) is below 25° C., wherein the proportions of the soft phase and the hard phase total 100% by weight and the proportion of the hard phase in the elastomeric block copolymers is from 5 to 40% by weight and the relative amount of 1,2 linkages of the diene, based on the sum of 1,2- and 1,4-cis/trans-linkages, is less than 15%;
15 to 40% by volume of at least one thermally conductive filler material (II) as component (II) having a weight median particle diameter (D50) of from 1 to 200 ?m,
which consists of at least one ceramic material and/or graphite;
wherein components (I) and (II) total 100% by volume;
0.1 to 10% by weight of at least one chemical foaming agent as component (Y);
wherein components (X) and (Y) total 100% by weight; and
the thermal conductivity K is more than 0.4 W/m?K.
US Pat. No. 10,920,039

FLAME-RETARDANT RESIN COMPOSITION AND FLAME-RETARDANT RESIN MOLDED ARTICLE

TOYO STYRENE CO., LTD., ...

1. A flame-retardant resin composition comprising:a styrene-based resin;
a brominated polymer-based flame retardant;
an epoxy compound;
an antioxidant; and
a halogen capture agent for improving a thermal stability of the brominated polymer-based flame retardant, the halogen capture agent consisting of a dolomite-based compound and a hydrotalcite-based compound, wherein
a content of bromine is 18 to 42% by mass,
4 to 25 parts by mass of the epoxy compound, 0.8 to 7 parts by mass of the antioxidant and 0.8 to 15 parts by mass of the halogen capture agent based on a total of 100 parts by mass of the styrene-based resin and the brominated polymer-based flame retardant are present, and
the brominated polymer-based flame retardant has the following features (a) to (f):
(a) the brominated polymer is a brominated styrene-butadiene block copolymer having butadiene and styrene as a monomer component;
(b) a content of the styrene monomer in the copolymer before bromination is 5 to 90% by mass;
(c) 1,2-butadiene is contained in the butadiene;
(d) a weight average molecular weight (Mw) is 1000 or more;
(e) a content of unbrominated nonaromatic double bonds determined by 1H-NMR spectroscopy is less than 50% based on a content of nonaromatic double bonds of the copolymer before bromination; and
(f) 5% weight reduction temperature obtained by thermogravimetric analysis (TGA) is 200° C. or higher.
US Pat. No. 10,920,807

USE OF TREATING ELEMENTS TO FACILITATE FLOW IN VESSELS

CRYSTAPHASE PRODUCTS, INC...

1. A method of improving flow distribution of one or more streams in a process vessel comprising:passing the one or more streams through an upstream processing zone and a downstream processing zone within the process vessel, the upstream processing zone and downstream processing zone each containing one or more beds of processing materials, wherein the processing materials comprise catalyst; and
passing the one or more streams through a redistribution treating zone located between, and adjacent to both of, the upstream processing zone and downstream processing zone, wherein the entire depth of the redistribution zone comprises a plurality of individual, packed treating elements, and wherein the treating elements comprise a material other than the catalyst of the processing materials,
wherein the redistribution treating zone has a depth of four feet or less,
and wherein the treating elements have a hollow tube shape,
and wherein the treating elements are up to 100 times the size of the individual processing materials within the process vessel.
US Pat. No. 10,919,271

COMPOSITE MOLDED ARTICLE AND METHOD OF MANUFACTURING SAME

Toray Industries, Inc., ...

1. A composite molded article layered with (A), (B) and (C) in this order:(A) a fiber-reinforced resin molded article comprising a fiber-reinforced resin having a polyamide-based resin as a matrix resin;
(B) a molded article comprising a modified vinyl-based copolymer; and
(C) a molded article comprising a styrene-based resin,
wherein the modified vinyl-based copolymer of the molded article (B) comprises a copolymer obtained by copolymerizing 0.1 to 10% by weight of an unsaturated carboxylic acid and 90 to 99.9% by weight in total of an aromatic vinyl-based monomer and a vinyl cyanide-based monomer.
US Pat. No. 10,920,040

TRANSPARENT PLASTIC SUBSTRATE AND PLASTIC LENS

HOYA LENS THAILAND LTD., ...

1. A plastic lens consisting essentially of:a transparent plastic substrate comprising:
a resin component comprising a (thio) urethane resin obtained by reaction of bis(isocyanatomethyl)bicyclo [2.2.1] heptane, pentaerythritoltetrakis(3-mercaptopropionate), and 1,2-bis(2-mercaptoethylthio)-3-mercaptopropane;
a benzotriazole compound in an amount of 0.10-2.00 parts by mass per 100 parts by mass of the resin component; and
at least one a functional layer selected from a group consisting of a cured film, a primer layer, an antireflection film and a water repellent film,
wherein the cured film is formed by a coating liquid comprising an organosilicon compound and one or more fine particles being selected from the group consisting of tin oxide, silicon oxide, zirconium oxide and titanium oxide, and
wherein the transparent plastic substrate has a cut rate of light having a wavelength of 410 nm of 50% or more, and
wherein the benzotriazole compound is at least one selected from 2-(3-tert-butyl-2-hydroxy-5-methylphenyl)-5-chloro-2H-benzotriazole and 2-(3-tert-butyl-2-hydroxy-5-ethylphenyl)-5-chloro-2H-benzotriazole.
US Pat. No. 10,923,737

SEPARATOR, AND FUEL CELL STACK COMPRISING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A separator comprising a plurality of unit bodies continuously arranged along a first direction and arranged apart at predetermined intervals along a second direction orthogonal to the first direction and a connecting portion connecting two unit bodies adjacent along the second direction,wherein each of the unit bodies has a wedge shape having a first inclined surface and a second inclined surface, connected at a predetermined angle at a vertex portion,
wherein two unit bodies adjacent along the second direction are arranged so that each vertex portion is not coaxially located with respect to a virtual line parallel to the second direction, and
wherein the connecting portion comprises at least two inclined portions for connecting the first inclined surfaces of the two unit bodies adjacent along the second direction.
US Pat. No. 10,920,297

HIGH-STRENGTH SEAMLESS STEEL PIPE FOR OIL COUNTRY TUBULAR GOODS AND METHOD OF PRODUCING THE SAME

JFE STEEL CORPORATION, T...

1. A high-strength seamless steel pipe for oil country tubular goods having a yield strength (YS) of 866 MPa or higher, the steel pipe having a chemical composition comprising, by mass %:C: 0.20% to 0.50%;
Si: 0.05% to 0.40%;
Mn: 0.3% to 0.9%;
P: 0.015% or less;
S: 0.005% or less;
Al: 0.005% to 0.1%;
N: 0.006% or less;
Cr: more than 0.6% and 1.7% or less;
Mo: more than 1.0% and 3.0% or less;
V: 0.02% to 0.3%;
Nb: 0.001% or more and less than 0.01%;
B: 0.0003% to 0.0030%;
O: 0.0030% or less;
Ti: 0.003% to 0.025%; and
a remainder including Fe and unavoidable impurities,
wherein a ratio of Ti to N is in a range of 2.0 to 5.0,
the steel pipe has a microstructure including (i) tempered martensite having a volume ratio of 95% or more, and (ii) prior austenite grains having a grain size number of 8.5 or more, and
in a cross-section perpendicular to a rolling direction of the steel pipe (i) a number of nitride-based inclusions having a particle size of 4 ?m or more is 100 or less per 100 mm2, (ii) a number of nitride-based inclusions having a particle size of less than 4 ?m is 1000 or less per 100 mm2, (iii) a number of oxide-based inclusions having a particle size of 4 ?m or more is 40 or less per 100 mm2, and (iv) a number of oxide-based inclusions having a particle size of less than 4 ?m is 400 or less per 100 mm2.
US Pat. No. 10,921,322

METHODS FOR DETECTING A MARKER FOR ACTIVE TUBERCULOSIS

KEI INTERNATIONAL LIMITED...

1. A method of detecting a marker for active tuberculosis, consisting essentially of the steps of:i) providing a sample from a human or animal suspected of having active tuberculosis;
ii) scavenging away anti-cholesterol antibodies from the sample by exposing said sample to a sterol lipid immobilised on a substrate, wherein said sterol lipid is cholesterol or a derivative thereof;
iii) obtaining at least two fractions of said sample either before or after exposing said sample to said sterol lipid;
iv) exposing a first of said sterol lipid exposed fractions to a substrate carrying an immobilised mycolic acid derived antigen;
v) exposing a second of said sterol lipid exposed fractions to a substrate not carrying an immobilised mycolic acid derived antigen; or storing at least part of the second of said fractions until step vi), skipping the step of exposing the second of said fractions to a substrate not carrying an immobilised mycolic acid derived antigen;
vi) exposing at least part of the sample fraction exposed in step iv) to a test substrate carrying an immobilised mycolic acid derived antigen and exposing at least part of the sample fraction exposed or stored in step v) to a control substrate carrying an immobilised mycolic acid derived antigen;
vii) detecting binding of antibodies to the antigen of step vi) in an end-point assay; and
viii) comparing a degree or extent of binding between the test and control substrates, wherein any observed lesser binding to the test substrate being an indicator of the presence of antibodies to the antigen in the sample that indicates active tuberculosis in the human or animal from which the samples originated; and
wherein prior to step vi), the test and control substrate of step vi) have not been preincubated with a dilution of said sample derived from a human or animal suspected of having active tuberculosis.
US Pat. No. 10,919,017

AQUEOUS DISPERSION, METHOD FOR MANUFACTURING THE SAME, AND IMAGE FORMING METHOD

FUJIFILM CORPORATION, To...

1. An aqueous dispersion comprising:a microcapsule that includes a shell having a three-dimensional cross-linked structure containing at least one bond selected from a urethane bond or a urea bond, and includes a core, in which at least one of the shell or the core has a polymerizable group;
a dispersant in which at least one bond selected from a urethane bond or a urea bond, and an anionic group are contained, a weight-average molecular weight is 5000 or more, and an anionic group value, which is the number of millimoles of the anionic group contained in 1 g of the dispersant, is from 0.10 mmol/g to 2.50 mmol/g; and
water.
US Pat. No. 10,921,323

METHOD FOR THE IMMUNOLOGICAL DIAGNOSIS OF A SAMPLE WITH A POTENTIAL INFECTION WITH AN ARBOVIRUS AND TEST KITS SUITABLE FOR THIS PURPOSE

Mikrogen GmbH, Neuried (...

1. A method for the immunological differential diagnosis of a sample from a human patient with a potential infection with an arbovirus, whereina) a sample is brought into contact with a plurality of antigens that, separated from each other, are applied to a solid phase, wherein at least the following antigens are used:
aa) the non-structural protein 1 of a Dengue virus serotype 2 or an immunologically reactive part thereof having at least 40 amino acids,
bb) an envelope protein of a Dengue virus serotype 2 or an immunologically reactive part thereof having at least 40 amino acids,
cc) an envelope protein of a Chikungunya virus or an immunologically reactive part thereof having at least 40 amino acids,
dd) the non-structural protein 1 of a Zika virus or an immunologically reactive part thereof having at least 40 amino acids and
ee) an envelope protein of a Zika virus or an immunologically reactive part thereof having at least 40 amino acids,
b) the solid phase of a) is washed to separate non-specific bindings,
c) anti-human IgG and/or anti-human IgM antibodies coupled to a signal-generating agent are added to the washed solid phase of b) and any immune complex formed is detected by a signal from the signal-generating agent, and
d) any signal generated in step c) is compared to a negative and positive control, and the presence and/or absence of IgG and/or IgM antibodies against the same antigens is determined by comparing any signal generated in c) with the negative and positive control.
US Pat. No. 10,923,739

FUEL CELL SUB-ASSEMBLY AND METHOD OF MAKING IT

1. A sub-assembly for an electrochemical stack comprising,a) a bipolar plate having upper and lower faces and an edge between the upper and lower faces, the upper and lower faces both containing flow fields, an inner face of the anode plate and/or the cathode plate having an elongated step or key open to an edge of the bipolar plate; and,
b) sealing material bonded to the bipolar plate and extending from the upper face of the bipolar plate, around the edge of the bipolar plate, and onto the lower face of the bipolar plate, wherein the sealing material extends into the step or key.
US Pat. No. 10,920,043

SHEETS OF STARCH BASED PACKING MATERIAL, STARCH PELLETS FOR SHEET EXTRUSION AND METHODS FOR FORMING THE PELLETS AND SHEETS

NewStarch Solutions, LLC,...

1. A method for making a foam-expanded material, the method comprising:feeding a collection of starch resin in pellet form into a single screw extruder with sufficient water to act as an expanding agent, wherein the starch resin pellets have an individual density of at least about 71 lbs/ft3; and
extruding the feed material in a molten state through a die after a dwell time in the extruder barrel of no more than about 2 minutes to form an expanded extrudate having a density of no more than about 5 lbs/cubic foot, wherein the screw RPM is from about 100 to about 800.
US Pat. No. 10,921,324

COMPOSITIONS AND METHODS RELATED TO THE METHYLATION OF HISTONE H1.0 PROTEIN

AELAN CELL TECHNOLOGIES, ...

1. An in vitro method for dimethylating n histone H1.0 peptide or a histone H1.0 protein comprising contacting the protein or peptide with a methyltransferase enzyme and a methyl donor under conditions that produce a specifically dimethylated protein or peptide, wherein greater than 50% of the produced protein or peptide is specifically dimethylated at a lysine residue corresponding to K180 of a human histone H1.0 protein, and wherein the methyltransferase enzyme is G9A methyltransferase or GLP methyltransferase.
US Pat. No. 10,920,044

CARBOHYDRATE-BASED PLASTIC MATERIALS WITH REDUCED ODOR

BIOLOGIQ, INC., Idaho Fa...

1. A sustainable plastic material exhibiting reduced odor comprising:a polymeric resin;
an organic odor-reducing agent;
a carbohydrate-based polymeric material, wherein in the absence of the organic odor-reducing agent, the carbohydrate-based polymeric material would lend a characteristic burned carbohydrate odor to the sustainable plastic material; and
wherein the organic odor-reducing agent comprises more than 0% but no more than 0.1% of the plastic material.
US Pat. No. 10,921,325

COMPOSITION FOR ANTICANCER ADJUVANT COMPRISING RIP3 EXPRESSION PROMOTER AS ACTIVE INGREDIENT, METHOD FOR SCREENING ANTICANCER ADJUVANT WHICH PROMOTES RIP3 EXPRESSION AND ENHANCES SENSITIVITY OF ANTICANCER AGENT, AND METHOD FOR MONITORING SENSITIVITY OF AN

AJOU UNIVERSITY INDUSTRY-...

1. A method for enhancing an anticancer chemotherapeutic drug sensitivity in a subject in need of the anticancer drub treatment, comprising administering an effective amount of a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent to the subject, wherein the RIP3 protein expression inducing agent is a demethylating agent which is selected from 5-aza-2?-deoxycytidine (5-AD), 5-azacytidine (5-AZA) and RG108, wherein the anticancer chemotherapeutic drug is selected from Doxorubicin, Etoposide, Paclitaxel, Fluorouracil, Camptothecin and Cisplatin.
US Pat. No. 10,919,020

AIR FILTERS WITH FUNCTIONALIZED NANOTUBE COMPOSITIONS TO CONTROL PATHOGENS SUCH AS SARS COV-2 (CORONAVIRUS)

Molecular Rebar Design, L...

18. An air filter comprising a filter media wherein the filter media comprises a plurality of discrete carbon nanotubes in an amount of from about 0.5 g to about 25 g of nanotubes per square meter of said filter media and wherein the air filter further comprises a coronavirus at least partially adhered to the plurality of discrete carbon nanotubes.
US Pat. No. 10,920,045

ELASTOMERIC COMPOSITION COMPRISING GRAPHENE AND TIRE COMPONENTS COMPRISING SAID COMPOSITION

DIRECTA PLUS S.P.A., Com...

1. An elastomeric composition comprising, based upon parts by weight per 100 parts by weight of rubber (phr):(A) 100 phr of a blend of rubbers comprising a styrene-butadiene copolymer (SBR) and at least 20% by weight of an isoprene polymer;
(B) from 10 to 30 phr of silica having a BET surface area measured using nitrogen of from 40 to 600 m2/g;
(C) from 10 to 50 phr of amorphous carbon black; and
(D) from 2 to 30 phr of graphene,
characterized in that said graphene comprises nanoplatelets of graphene, wherein at least 90% of said nanoplatelets have a lateral size (x, y) from 500 to 15000 nm and a thickness (z) from 0.34 to 8 nm, wherein the C/O ratio is ?100:1; and said nanoplatelets of graphene being at least one of i) free from surfactant or ii) comprising an amount of less than 1% by weight of surfactant deposited on the surface thereof;
wherein said elastomeric composition exhibits:
values of elastic modulus E? at deformation rates from 0.01 to 10% that are from 25 to 55% higher than the values of elastic modulus E? at the same deformation rates of the same elastomeric composition which does not comprise said graphene; and
a decrease of elastic modulus at a deformation rate of about 10% which is greater in the elastomeric composition comprising said graphene than the decrease of elastic modulus shown by the same elastomeric composition which does not comprise said graphene at the same deformation rate of about 10%.
US Pat. No. 10,920,301

ALUMINUM ALLOY CASTING HAVING SUPERIOR HIGH-TEMPERATURE STRENGTH AND THERMAL CONDUCTIVITY, METHOD FOR MANUFACTURING SAME, AND ALUMINUM ALLOY CASTING PISTON FOR INTERNAL COMBUSTION ENGINE

Nippon Light Metal Compan...

1. An aluminum alloy casting, characterized by having a chemical composition comprisingSi: 12.0 to 13.5 mass %
Cu: 4.5 to 5.5 mass %
Mg: 0.6 to 1.0 mass %
Ni: 0.7 to 1.3 mass %
Fe: 1.15 to 1.25 mass %
Ti: 0.10 to 0.2 mass %
P: 0.004 to 0.02 mass % and
a balance of Al and unavoidable impurities,
provided that the ratio Cu/Ni of the contents of Cu and Ni is 3.83 or more,
wherein the alloy contains Al—Fe—Si based crystallites and, in an observed field of view of 0.2 mm2, the major axis length of the Al—Fe—Si based crystallites is 96 ?m or less in terms of the average length of 10 crystallites from the largest major axis length down.
US Pat. No. 10,918,765

DECELLULARIZATION AND RECELLULARIZATION OF WHOLE ORGANS

University of Vermont and...

1. A method of recellularizing a decellularized lung tissue, comprising the steps of:decellularizing an isolated lung tissue sample to form a decellularized lung tissue, wherein the isolated lung tissue sample is a whole organ or a portion thereof;
applying a first coating to at least a portion of the decellularized lung tissue, wherein the first coating comprises a hydrogel sealing agent comprising a hydrogel solution comprising alginate;
applying a second coating to the portion of tissue, wherein the second coating comprises one or more crosslinking agents that crosslink the alginate coated on the decellularized lung tissue; and
contacting the decellularized lung tissue with at least one cell type;
wherein the hydrogel sealing agent coating prevents leakage of liquids and gases from the decellularized isolated tissue sample.
US Pat. No. 10,919,021

STERILE CHROMATOGRAPHY RESIN AND USE THEREOF IN MANUFACTURING PROCESSES

Genzyme Corporation, Cam...

1. A method of reducing bioburden of a chromatography resin comprising:exposing a container comprising a composition comprising (i) a chromatography resin and (ii) a liquid comprising between about 15 mM and about 35 mM mannitol, between about 15 mM and about 35 mM sodium ascorbate, between about 15 mM and about 35 mM histidine, and between about 15 mM and about 35 mM methionine to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, wherein mannitol, sodium ascorbate, histidine, and methionine are together present in the liquid in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after exposure to the dose of gamma-irradiation.
US Pat. No. 10,919,790

METHOD FOR REMOVING SELENIUM AND APPARATUS FOR REMOVING SELENIUM

MITSUBISHI POWER ENVIRONM...

1. A method for removing selenium from a wastewater from a facility that gasifies a coal fuel containing selenium in a reducing atmosphere, the method comprising:a valence change step of adding an oxidant to the wastewater containing selenium, and oxidizing selenium having a valence lower than +4 to change the valence of the selenium to +4, and
a solid-liquid separation step of adding a flocculant to the wastewater, forming a floc containing the selenium for which the valence has been changed in the valence change step, and subjecting the floc to solid-liquid separation,
wherein the valence change step includes a step of adjusting a pH of the wastewater to 4 before adding the oxidant to the wastewater,
the solid-liquid separation step includes a step of adjusting a pH of the wastewater to 7 using an alkali agent before adding the flocculant to the wastewater,
wherein hydrogen peroxide is used as the oxidant in the valence change step and an oxidation-reduction potential of the wastewater is controlled to a value of at least 393 mV but not more than 433 mV so as to change the valence of the selenium to +4, or sodium hypochlorite is used as the oxidant in the valence change step and an oxidation-reduction potential of the wastewater is controlled to a value of at least 630 mV but not more than 900 mV so as to change the valence of the selenium to +4,
the flocculant comprises an inorganic flocculant and a polymer flocculant, and
the polymer flocculant is an anionic polymer flocculant or a nonionic polymer flocculant.
US Pat. No. 10,920,046

RUBBER COMPOSITION INCLUDING A DIENE ELASTOMER COMPRISING CARBONATE FUNCTIONAL GROUPS

COMPAGNIE GENERALE DES ET...

1. A rubber composition, comprising:a reinforcing filler and an elastomer, the elastomer comprising units of a 1,3-diene monomer and bearing carbonate functions, each present in a 1,3-dioxolan-2-one ring.
US Pat. No. 10,918,766

AGENT FOR HYPODERMIC INJECTION

Motejo Ltd., Tokyo (JP)

1. An agent for hypodermic injection comprising:a hydrogel containing carboxymethylcellulose and sintered hydroxyapatite particles, wherein
a content of the sintered hydroxyapatite particles is 1 to 60% by mass based on the total mass of the agent,
an average particle diameter of the sintered hydroxyapatite particles is 1 ?m or less,
4% or more of the sintered hydroxyapatite particles have a particle diameter that ranges from 5 ?m or more to 30 ?m or less, and
a viscosity of the hydrogel is in a range from 60 to 1000 mPa·s.
US Pat. No. 10,919,022

EXHAUST GAS PURIFYING AGENT FOR AUTOMOBILES AND METHOD OF PRODUCING THEREOF

EISHIN CO., LTD., Minato...

1. An exhaust gas purifying agent, comprising an aqueous composition comprising:a) a tourmaline fine powder,
b) a porous material fine powder,
c) a fucoidan extracted from a seaweed, and
d) an amino peptide and/or an alginic acid extracted from a seaweed.
US Pat. No. 10,920,047

INTER-PENETRATING ELASTOMER NETWORK DERIVED FROM GROUND TIRE RUBBER PARTICLES

1. A method for preparing a polymeric matrix, comprising:combining vulcanized rubber particles, an auxiliary polymer comprising a reactive moiety, and an organometallic compound into a mixture, so as to induce delamination of a rubber matrix within the vulcanized rubber particles as coordinated with disrupting sulfidic linkages, so as to induce crosslinking of the auxiliary polymer into the polymeric matrix, and so as to induce a chemical reaction between the reactive moiety and a polyaromatic hydrocarbon, whereby the polymeric matrix sequesters the polyaromatic hydrocarbon.
US Pat. No. 10,921,328

BIOMARKERS FOR EARLY DETERMINATION OF A CRITICAL OR LIFE THREATENING RESPONSE TO ILLNESS AND/OR TREATMENT RESPONSE

FIO CORPORATION, Toronto...

1. A method of determining the likelihood of a test individual having a critical and/or life threatening response to malaria, said method comprising:(i) detecting and quantifying a level of each of three protein biomarkers in a sample from the test individual, wherein the test individual has not been diagnosed or differentially diagnosed as having the suspected illness, wherein said protein biomarkers are angiopoietin-2 (Ang-2), 10 kDa interferon gamma-induced protein (IP-10), and soluble intercellular adhesion molecule-1 (siCAM-1),
(ii) utilizing the quantified levels of each said protein biomarkers from said sample in a classifier derived from testing said protein biomarkers in one or more control populations (iii) making a determination as to whether said individual is at an increased risk of the critical and/or life threatening response as a result of application of said classifier.
US Pat. No. 10,919,023

PRODUCING BDO VIA HYDROFORMYLATION OF ALLYL ALCOHOL MADE FROM GLYCERIN

Lyondell Chemical Technol...

1. A method comprising:producing allyl alcohol from glycerin in the presence of 0.5 to 10 mole percent of a rhenium catalyst, wherein the rhenium catalyst is selected from the group consisting of rhenium dioxide, methyltrioxorhenium (MTO), rhenium trioxide and a combination thereof,
hydroformylating, with synthesis gas, allyl alcohol in a feed comprising allyl alcohol derived from glycerin, to produce a hydroformylation product comprising 4-hydroxybutyraldehyde (HBA) and 3-hydroxy-2-methylpropionaldehyde (HMPA) in a ratio of HBA:HMPA of at least 11.5:1; and
producing a 1,4-butanediol (BDO) product comprising BDO and 1,3-methylpropanediol (MPD) via hydrogenation of at least a portion of the hydroformylation product.
US Pat. No. 10,920,048

TYRE COMPRISING HYDROTHERMALLY CARBONIZED LIGNIN

Nokian Renkaat Oyj, Noki...

1. A method for manufacturing a pneumatic tyre for a vehicle, the method comprisingreceiving a rubber based component comprising lignin that has been treated by hydrothermal carbonization,
arranging the rubber based component onto a building drum to form a tubular preform,
expanding the tubular preform to form a preform of a pneumatic tyre,
arranging a metal component and a textile component onto the preform of a tyre, thereby manufacturing a preform of a pneumatic tyre comprising the rubber based component comprising lignin that has been treated by hydrothermal carbonization, the metal component and the textile component, and
curing the preform of a pneumatic tyre, thereby bonding the components together by means of curing and thereby receiving the pneumatic tyre for a vehicle, the pneumatic tyre comprising a cured rubber based component.
US Pat. No. 10,921,329

METHODS FOR DETECTING ANTIBODIES

THE REGENTS OF THE UNIVER...

1. A complex comprising a therapeutic monoclonal antibody and a peptide, said complex comprising:a) a therapeutic monoclonal antibody selected from the group consisting of bevacizumab, rituximab, and trastuzumab, wherein the therapeutic monoclonal antibody is not complexed to an epitope of a target protein; and
b) a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, and 11-15, wherein the peptide is complexed to said therapeutic monoclonal antibody, said peptide having a length of about 5-15 amino acids and comprising a mimetope recognized by the therapeutic monoclonal antibody, wherein the mimetope comprises a linear sequence of amino acids which is different than a linear sequence of amino acids in the epitope of the target protein, and
wherein when the therapeutic monoclonal antibody is rituximab, the peptide consists of the amino acid sequence of SEQ ID NO: 4 or 5;
wherein when the therapeutic monoclonal antibody is bevacizumab, the peptide consists of the amino acid sequence of any one of SEQ ID NOs: 11-14; and
wherein when the therapeutic monoclonal antibody is trastuzumab, the peptide consists of the amino acid sequence of SEQ ID NOs: 15.
US Pat. No. 10,918,768

HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES

Stratatech Corporation, ...

1. A method for providing cells expressing heterologous keratinocyte growth factor-2 (KGF-2) comprising:a) providing immortalized keratinocytes selected from the group consisting of near-diploid immortalized keratinocytes (NIKS) cells and cells derived from NIKS cells and an expression vector comprising a DNA sequence encoding KGF-2 operably linked to a regulatory sequence selected from an involucrin promoter and a K14 promoter;
b) introducing said expression vector to said immortalized keratinocytes and selecting immortalized keratinocytes that are stably transfected with the DNA sequence encoding KGF-2 operably linked to a regulatory sequence selected from an involucrin promoter and a K14 promoter; and
c) culturing said stably transfected immortalized keratinocytes to form an in vitro human skin equivalent comprising stratified squamous epithelia that expresses KGF-2, wherein said in vitro human skin equivalent is characterized in having correct tissue architecture including the formation of desmosomes, hemidesmosomes, and basal lamina.
US Pat. No. 10,919,024

RHENIUM CATALYSTS FOR GLYCERIN TO ALLYL ALCOHOL CONVERSION

Lyondell Chemical Technol...

1. A method comprising:exposing glycerin to a temperature of greater than 140° C. in the presence of a catalyst comprising rhenium trioxide, rhenium dioxide, or a combination thereof to produce a product comprising allyl alcohol and 3-octanone,
wherein the catalyst is present in the range of 0.5 to 10 mole percent.
US Pat. No. 10,920,049

POLYMER COMPOSITION WITH HIGH FLEXIBILITY AND FLAME RETARDANCY

LEONI KABEL GMBH, Nuremb...

1. Polymer composition comprising at least the following components:(a) 24-32 wt.-% of a linear very low density polyethylene (VLDPE) composition having a density in the range from 0.85 g/cm3 to 0.95 g/cm3, as measured according to ISO 1183;
(b) 10-17 wt.-% of a polyolefin-elastomer, which is an ultra-low density random ethylene-octene copolymer having a glass transition temperature of ?50° C.;
(c) a flame retardant filler, wherein the flame retardant filler is present in an amount of 55-65 wt.-%;
(d) 0.1-3.0 wt.-% of an antioxidant; and
(e) 0.5-2.5 wt.-% of a coupling agent composition.
US Pat. No. 10,919,025

N2O REMOVAL FROM AUTOMOTIVE EXHAUST FOR LEAN/RICH SYSTEMS

BASF Corporation, Florha...

1. A nitrous oxide (N2O) removal catalyst composition for treating an exhaust stream of an internal combustion engine, the composition comprising:a platinum group metal component supported on a metal oxide-based support;
wherein the N2O removal catalyst composition is in a substantially reduced form such that it has an oxygen deficiency of about 0.05 mmol oxygen atoms/g or greater, and
wherein the N2O removal catalyst composition provides effective N2O removal under lean conditions at a temperature of about 350° C. or lower.
US Pat. No. 10,920,050

POLYETHYLENE COMPOSITION FOR BLOW MOLDING HAVING HIGH STRESS CRACKING RESISTANCE

Basell Polyolefine GmbH, ...

1. A polyethylene composition having the following features:1) density from 0.948 to 0.952 g/cm3 determined according to ISO 1183-1 at 23° C.;
2) ratio MIF/MIP from 12 to 25, where MIF is the melt flow index at 190° C. with a load of 21.60 kg, and MIP is the melt flow index at 190° C. with a load of 5 kg, both determined according to ISO 1133;
3) MIF from 18 to 40 g/10 min;
4) Mz equal to or greater than 1,200,000 g/mol, where Mz is the z-average molecular weight, measured by GPC;
5) ?0.02 from 38,000 to 55,000 Pa·s, wherein ?0.02 is the complex shear viscosity at an angular frequency of 0.02 rad/s, measured with dynamic oscillatory shear in a plate-plate rotational rheometer at a temperature of 190° C.;
6) long-chain branching index, LCBI, equal to or greater than 0.55, wherein LCBI is the ratio of the measured mean-square radius of gyration Rg, measured by GPC-MALLS, to the mean-square radius of gyration for a linear PE having the same molecular weight; and
7) ratio (?0.02/1000)/LCBI, which is ?0.02 divided by 1000 and LCBI, from 55 to 75.
US Pat. No. 10,921,331

HDL-ASSOCIATED PROTEIN BIOMARKER PANEL DETECTION

Cleveland Heartlab, Inc.,...

1. A system comprising:a) a sample from a subject with, or suspected of having, cardiovascular disease, wherein said sample comprises high density lipoprotein (HDL) particles, apolipoprotein A1 (ApoA1), or HDL-cholesterol;
b) a first component, wherein said first component comprises:
i) an Apolipoprotein C3 (ApoC3) binding agent, and/or
ii) an ApoC3 mass spectrometry standard; and
c) a second component comprising a detectably labeled apolipoprotein A1 (ApoA1) protein or fragment thereof, wherein said detectably labeled ApoA1 protein serves as a calibrator for normalizing levels of one or more HDL-associated proteins in said sample to the level of total HDL particles, ApoA1, or HDL-cholesterol present in said sample, wherein at least one of the one or more HDL-associated proteins is ApoC3.
US Pat. No. 10,920,051

RESIN COMPOSITION AND ELECTRICAL CABLE

SUMITOMO ELECTRIC INDUSTR...

1. A resin composition comprising:a resin component;
zinc oxide; and
an acetic acid remover,
wherein the resin component includes an ethylene-vinylacetate copolymer and a content of the ethylene-vinylacetate copolymer in the resin component is greater than or equal to 10% by mass,
wherein the resin component includes high-density polyethylene and a content of the high-density polyethylene is greater than or equal to 30 parts by mass and less than or equal to 75 parts by mass with respect to 100 parts by mass of the resin component,
wherein the acetic acid remover is an acid acceptor, a nitrogen-containing aromatic heterocyclic compound having a mercapto group, or a combination thereof,
wherein a mass ratio of the zinc oxide to the ethylene-vinylacetate copolymer is greater than or equal to 0.06 and less than or equal to 0.20, and
wherein a mass ratio of the acetic acid remover to the zinc oxide is greater than or equal to 0.1 and less than or equal to 10.
US Pat. No. 10,921,332

COLLAGEN IV BINDING ASSAY FOR THE DETECTION OF COLLAGEN VII

PHOENIX TISSUE REPAIR, IN...

1. A method for evaluating or processing a collagen VII preparation comprising determining the presence or amount of collagen VII in the preparation, the method comprising:(a) contacting the preparation or a sample of the preparation with collagen IV, or a fragment thereof;
(b) contacting the sample contacted with collagen IV, or a fragment thereof, with an anti-collagen VII antibody that binds to collagen VII in a collagen VII-collagen IV complex;
(c) measuring the level of collagen VII bound to collagen IV by detecting and quantifying anti-collagen VII antibody bound to collagen VII in the collagen VII-collagen IV complexes;
(d) detecting and/or quantifying the amount of collagen VII in the sample, thereby determining the presence or amount of collagen VII in the preparation; and
(e) comparing the value determined for the presence or amount of collagen VII in the sample with a reference value, thereby evaluating or processing the collagen VII preparation;
wherein the collagen VII preparation is a collagen VII substance preparation or a collagen VII drug product preparation.
US Pat. No. 10,921,333

CONTROL OF PH IN AQUEOUS UREA-CONTAINING SOLUTIONS UTILIZING AMINO ACID-CONTAINING COMPOSITIONS

Siemens Healthcare Diagno...

1. A composition comprising an aqueous diagnostic quality control or calibration reagent disposed in a closed system, the composition comprising:urea present in a concentration in a range of from about 0.1 mM to about 150 mM;
at least one buffer; and
ornithine, wherein a ratio of urea to ornithine is in a range of from about 0.1:1 to about 100:1; and
wherein the pH of the aqueous quality control or calibration reagent varies by +/?1.0 or less of the original pH following storage of the composition, and further wherein formation of ammonia in the aqueous diagnostic quality control or calibration reagent is substantially reduced by at least 5% following storage of the composition when compared to a composition prepared in the absence of ornithine and following storage thereof; and
wherein the aqueous diagnostic quality control or calibration reagent is for utilization with a diagnostic sensor.
US Pat. No. 10,919,028

METHOD FOR THE PREPARATION OF A SYNTHETIC FAUJASITE MATERIAL COMPRISING MONODISPERSE NANOPARTICLES COMPOSED OF SINGLE NANOCRYSTALS

CENTRE NATIONAL DE LA REC...

1. A method for the preparation of a synthetic faujasite material having monodisperse nanoparticles composed of single nanocrystals, said nanoparticles having a size going from 5 to 400 nm and a silicon to aluminum molar ratio Si/Al going from 1 to 2.5, wherein said method comprises the following steps:A) separately preparing a clear aqueous aluminate suspension A comprising at least one source of aluminum and at least one source of an alkali metal M1, and a clear aqueous silicate suspension B comprising at least one source of silicon and at least one source of an alkali metal M1, said separate preparations being prepared at 20-25° C.;
B) admixing the clear aqueous aluminate suspension A and the clear aqueous silicate suspension B until a resulting aqueous suspension is obtained, said resulting aqueous suspension being free of organic-templating agents and having the following molar composition:
x1M12O:yAl2O3:10SiO2:zH2O  (I)in which:0.1?y?5,
20?z?400, and preferably 20?z?320,
5?x1?13;
wherein in step B), the clear aqueous silicate suspension B only is cooled to a temperature of 0° to 5° C., then the clear aqueous aluminate suspension A is added drop wise to the cooled clear aqueous silicate suspension B, while said clear aqueous silicate suspension B is kept at a temperature going from 0° to 5° C. for the duration of the dropwise addition,
C) aging the resulting suspension of step 2) at a temperature going from about 20° C. to about 30° C. to form nuclei;
D) heating the resulting suspension of step 3) at a temperature going from about 40° C. to about 150° C., for a period of time sufficient to produce the desired synthetic faujasite material comprising monodisperse nanoparticles composed of single nanocrystals; and
E) recovering said synthetic faujasite material comprising monodisperse nanoparticles composed of single nanocrystals.
US Pat. No. 10,920,053

PROPYLENE IMPACT COPOLYMER BLENDS WITH IMPROVED GLOSS

ExxonMobil Chemical Paten...

1. A polymer blend comprising:(a) a propylene impact copolymer comprising a polypropylene component present in a continuous phase and a first elastomeric component present in a disperse phase; and
(b) a second elastomeric component, wherein the second elastomeric component comprises a propylene-based elastomer containing 75 to 97 wt. % of propylene-derived units and from 3 to 25 wt. % of ethylene and/or C4-C20 ?-olefin derived units and has an mm propylene triad tacticity of at least 75%, and a heat of fusion of less than 75 J/g;
wherein the interfacial tension between the second elastomeric component and the impact copolymer is at least 2.7 mN/m.
US Pat. No. 10,919,029

MODIFIED CATALYST WITH STRUCTURE TYPE MTW, A METHOD FOR ITS PREPARATION AND ITS USE IN A PROCESS FOR THE ISOMERIZATION OF AN AROMATIC C8 CUT

IFP Energies Nouvelles, ...

1. A process for the preparation of a catalyst comprising at least one zeolite with structure type MTW, a matrix, and at least one metal from group VIII of the periodic classification of the elements, comprising at least the following steps:i) providing at least one zeolite with structure type MTW,
ii) preparing a support by shaping said zeolite with a matrix,
iii) depositing at least one metal from group VIII of the periodic classification of the elements onto said support or onto said zeolite, wherein the depositing can be before or after the preparing of the support in step ii),
iv) bringing the catalyst obtained in step ii) or step iii), depending on the order in which they are carried out, into contact with steam at a partial pressure in the range 0.01 to 0.07 MPa, at a temperature in the range 300° C. to 400° C., for at least 0.5 hour, in a manner such that the mesopore volume of the catalyst is increased by at least 10% compared with the mesopore volume of the catalyst before the contact with steam.
US Pat. No. 10,920,054

RECYCLED POLYOLEFIN COMPONENT FOR HOUSEHOLD APPLIANCES

Electrolux Appliances Akt...

1. A component for household appliances, the component comprising a plastic mixture comprising recycled polyolefin composition deriving from post-consumer plastic and/or post industrial plastic materials and fillers, wherein the plastic mixture comprises:10-60% recycled polyolefin composition;
42-60% mineral filler;
15-40% reinforcing filler;
0-1% additive selected from the group consisting of antioxidants and lubricants; and
0-3% grafting polymer;
the percentages being by weight of the total plastic mixture,
wherein the mineral filler is selected from the group consisting of calcium carbonate and talc, andwherein the reinforcing filler is selected from the group consisting of glass fibers and natural fibers; andwherein the plastic mixture has a density of from 1246 kg/m3 to 1289 kg/m3.
US Pat. No. 10,920,055

HETEROPHASIC POLYPROPYLENE COMPOSITION WITH IMPROVED MECHANICAL AND OPTICAL PROPERTIES

BOREALIS AG, Vienna (AT)...

1. A heterophasic polypropylene composition having an MFR230/2.16 according to ISO1133 of at most 6.0 g/10 min and comprising:a. ?80.0 wt. % of a polypropylene homopolymer and
b. <20.0 wt. % of an elastomeric ethylene-propylene rubber fraction,
c. a polymeric nucleating agent and
d. at least one further nucleating or clarifying agent;
wherein the heterophasic polypropylene composition further comprises a xylene soluble fraction (XCS) of 5.0 to 20.0 wt. % and the elastomeric ethylene-propylene rubber fraction (b) has an ethylene content C2(XCS) of 20.0 to 38.0 wt. %;
wherein the polypropylene homopolymer (a) has a melt flow rate MFR230/2.16 according to ISO1133 in the range of 1.0 to 6.0 g/10 min and an intrinsic viscosity (IV) according to ISO1628/1 in the range of 2.5 to 3.4 dl/g; and
wherein the elastomeric ethylene-propylene rubber fraction (b) has an intrinsic viscosity IV according to ISO1628/1 in the range of 1.4 to 2.1 dl/g.
US Pat. No. 10,921,336

AUTOMATED METHOD AND SYSTEM FOR OBTAINING AND PREPARING MICROORGANISM SAMPLE FOR BOTH IDENTIFICATION AND ANTIBIOTIC SUSCEPTIBILITY TESTS

BD KIESTRA B.V., Drachte...

1. An automated method for locating and selecting a colony of microorganisms on a culture dish and preparing a single sample suspension with the selected colony for multiple assays, wherein the method comprises the automated steps of:locating and selecting a colony of microorganisms on a culture dish;
obtaining a sample of the selected colony of microorganisms;
transferring the obtained sample into a container having an amount of a suspension medium, the container adapted to be received by a nephelometer;
preparing a sample suspension by transferring at least a portion of the obtained sample into the suspension medium using an automated pick tool;
automatically obtaining an aliquot of the prepared suspension;
dispensing a portion of the prepared suspension on a receptacle for a first assay;
transferring the first assay receptacle with the dispensed portion of the prepared sample thereon to an apparatus for performing mass spectrometry for identification of the sample of the selected colony of microorganisms;
determining a turbidity of a remaining portion of the prepared suspension for a second assay using an automated nephelometer;
automatically inoculating a sample container for the second assay with an aliquot of the remaining portion of the prepared suspension based on the turbidity and a predetermined amount of microorganism required for the second assay by, without dilution, automatically selecting a volume of the aliquot of the remaining portion of the prepared suspension that contains the predetermined amount of microorganisms;
automatically obtaining the selected volume of the aliquot that contains the predetermined amount of microorganism; and
automatically inoculating a receptacle for the second assay with the selected aliquot volume obtained from the remaining portion of the prepared suspension.
US Pat. No. 10,920,056

LOW DENSITY POLYOLEFIN RESINS WITH STIFFNESS, IMPACT BALANCE, AND HIGH DIMENSIONAL STABILITY

Equistar Chemicals, LP, ...

1. A composition comprising:(a) a polyolefin comprising a polypropylene homopolymer, a propylene-ethylene block copolymer, or combinations thereof, wherein the polyolefin is present in an amount ranging from about 55 wt. % to about 72 wt. %, based on a total weight of the composition;
(b) a first and a second elastomer that are not the same, wherein the combined weight percent of the first elastomer and the second elastomer ranges from about 18 wt. % to about 33 wt. %, based on the total weight of the composition wherein: (i) the first elastomer comprises an ethylene-based copolymer having a density from about 0.86 g/cm3 to about 0.88 g/cm3, wherein the first elastomer is present in an amount ranging from about 5 wt. % to about 15 wt. %, based on the total weight of the composition; and (ii) the second elastomer comprises an ethylene-octene copolymer having a density from about 0.85 g/cm3 to about 0.87 g/cm3 and a glass transition temperature below ?60° C., wherein the second elastomer is present in an amount ranging from about 10 wt. % to about 22 wt. %, based on the total weight of the composition;
(c) a filler present in an amount ranging from about 6 wt. % to about 12 wt. %, based on the total weight of the composition; and
(d) an additive package present in an amount ranging from about 0.5 wt. % to about 5 wt. %, based on the total weight of the composition;
wherein the composition has a density ranging from about 0.92 to about 0.99 g/cm3, an after-bake-mold-shrinkage (1 hours, 121° C.) ranging from about 0.7 percent to about 0.9 percent, a coefficient of linear thermal expansion ranging from about 5 to about 8 (10E-5 mm/mm/° C.), and a flexural modulus between about 1,400 MPa and about 2,500 MPa.
US Pat. No. 10,919,032

ANTIFOULING COMPOSITIONS AND METHODS

Florida State University ...

1. A composition comprising:an ion exchange resin, and
a polyelectrolyte, wherein the polyelectrolyte is adsorbed to at least a portion of a surface of the ion exchange resin, and the polyelectrolyte has a weight average molecular weight (Mw) of at least 100,000 g/mol.
US Pat. No. 10,920,057

POLYPROPYLENE COMPOSITION FOR FOAMING APPLICATIONS

BOREALIS AG, Vienna (AT)...

1. A polypropylene composition (C), comprising:a) at least 20 wt. %, based on the overall weight of the polypropylene composition (C), of a heterophasic propylene copolymer (HECO1) comprising:
i) a matrix (M) comprising a first propylene polymer (PP1), and
ii) an elastomeric propylene copolymer (E),
b) at least 30 wt. %, based on the overall weight of the polypropylene composition (C), of a second propylene polymer (PP2),
c) a propylene homopolymer (H-PP3) having a melt flow rate MFR2 (230° C.) determined according to ISO 1133 below 50 g/10 min,
d) an adhesion promoter (AP), and
e) an inorganic filler (F),
wherein said first propylene polymer (PP1) and said second propylene polymer (PP2) have melt flow rates MFR2 (230° C.) determined according to ISO 1133 above 50 g/10 min.
US Pat. No. 10,923,754

POLYMER BLEND PROTON EXCHANGE MEMBRANE AND METHOD FOR MANUFACTURING THE SAME

1. A vanadium redox battery comprising:(i) at least one vanadium ion; and
(ii) a polymer blend proton exchange membrane comprising a blend of:
(a) a soluble polymer comprising a polymer selected from the group consisting of polysulfone, polyethersulfone and polyvinylidene fluoride, a weight-average molecular weight of the soluble polymer in the range of 35,000 to 65,000 grams per mole (g/mol), wherein the soluble polymer is present in an amount of 10% to 50% based on the total weight of the polymer blend proton exchange membrane; and
(b) a sulfonated polymer comprising a polymer selected from the group consisting of sulfonated poly(ether-ether-ketone) having a degree of sulfonation of 98% and sulfonated poly(ether-ketone) having a degree of sulfonation of 105%, and
wherein the soluble polymer and sulfonated polymer are cross-linked.
US Pat. No. 10,919,803

PROCESS FOR MANUFACTURING A MILK OF SLAKED LIME OF GREAT FINENESS AND MILK OF LIME OF GREAT FINENESS THEREBY OBTAINED WITH PROCESS WATER

S. A. Lhoist Recherche et...

1. A process for manufacturing a milk of lime of great fineness comprising at least the steps ofa) providing a lime compound selected from the group consisting of quicklime, a first lime compound and their mixture said first lime compound being, selected front the group consisting of prehydrated lime obtained by the addition of a first water to quicklime, paste of lime obtained by the addition of a second water to quicklime, paste of lime obtained by the addition of a third water to prehydrated lime, paste of lime obtained by the addition of prehydrated lime to a third water and their mixture, and
b) forming a milk of slaked lime of great fineness with, said lime compound by the addition of a fourth water to said lime compound or by the addition of the first lime compound to a fourth water,
characterized in that at least one of the first, second, third or fourth water is process water selected from the group consisting of alkaline water, saline water, sulfate water comprising from 3 to 300 g solute/L and in that at least one of the first, second, third or fourth water is added to said lime compound, said milk of lime of great fineness having slaked lime particles presenting a d50 greater than or equal to 1 ?m and lower than or equal to 6 ?m, measured by laser diffraction using methanol as carrier solvent after screening of the milk of lime at 2 mm through a sieve for removing the grits.
US Pat. No. 10,919,804

METHOD FOR PRODUCING CEMENTING MATERIALS PRODUCED FROM THE RECYCLING OF INDUSTRIAL WASTE FROM THE PROCESSES OF PRODUCING CERAMICS AND BRICKS

1. A method for producing cementitious materials made from the recycling of industrial waste from the processes of production of ceramics and brick, comprising:a. selecting structural and nonstructural brick waste or byproducts, which have been fired at a temperature of between 500 and 1000° C.
b. selecting ceramic parts waste, which have been fired at a temperature of between 700 and 1200° C.
c. separately crushing the waste selected in steps a and b until obtaining particle sizes of between 10 and 80 microns.
d. mixing crushed fines resulting from step c to produce a cementitious material comprising from 40 to 60% of fines from brick waste and 40 to 60% of waste from ceramic parts.
US Pat. No. 10,920,060

MULTI-STAGE POLYMER COMPOSITION AND FILMS MADE THEREFROM

Rohm and Haas Company, P...

1. A polymer composition comprising a multi-stage polymer comprising:(a) 30 to 40 weight % of a cross-linked core, based on the total weight of the multi-stage polymer, comprising polymerized units derived from (i) 95 to 99.9 weight % of one or more alkyl(meth)acrylate monomers, and (ii) 0.1 to 5 weight % of one or more cross-linking monomers, graft-linking monomers, and combinations thereof, based on the total weight of the cross-linked core;
(b) 30 to 40 weight % of a first intermediate layer, based on the total weight of the multi-stage polymer, comprising polymerized units derived from (i) 95 to 100 weight % of one or more alkyl(meth)acrylate monomers, and (ii) 0 to 5 weight % of cross-linking monomers, graft-linking monomers, and combinations thereof, based on the total weight of the first intermediate layer;
(c) 10 to 20 weight % of a second intermediate layer, based on the total weight of the multi-stage polymer, comprising polymerized units derived from (i) 98 to 100 weight % of one or more alkyl(meth)acrylate monomers, styrenic monomers, and combinations thereof, and (ii) 0 to 2 weight % of one or more chain transfer agents, based on the total weight of the second intermediate layer; and
(d) 10 to 20 weight % of a shell, based on the total weight of the multi-stage polymer, comprising polymerized units derived from (i) 84 to 98 weight % of one or more alkyl(meth)acrylate monomers, styrenic monomers, and combinations thereof, (ii) 2 to 16 weight % of one or more monomers selected from the group consisting of acid functionalized monomers, hydroxyl-functionalized monomers, and combinations thereof, and (iii) 0 to 2 weight % of one or more chain transfer agents, based on the total weight of the shell.
US Pat. No. 10,920,062

COMPOSITION COMPRISING A MULTISTAGE POLYMER AND TWO DIFFERENT (METH)ACRYLIC POLYMERS, ITS METHOD OF PREPARATION AND ARTICLE COMPRISING IT

Arkema France, Colombes ...

1. A polymeric composition comprisingA. a (meth)acrylic polymer (P1), wherein said (meth)acrylic polymer (P1) comprises at least 50 wt % monomers chosen from C1 to C12 alkyl (meth)acrylates,
B. a multistage, core-shell polymer and
C. a (meth)acrylic polymer (P2), which is different from the (meth)acrylic polymer (P1), in either the mass average molecular weight, the composition of the polymer, or both, and wherein the (meth)acrylic polymer (P2) has a mass average molecular weight Mw above 50,000 g/mol,wherein the (meth)acrylic polymer (P1) has a mass average molecular weight Mw of less than 100,000 g/mol as measured by mass average molecular weight (Mw) of the polymers is measured with by size exclusion chromatography (SEC), and wherein the multi stage polymer comprisesa) one stage (A) comprising a polymer (A1) having a glass transition temperature of less than 0° C., and
b) one stage (B) comprising a polymer (B1) having a glass transition temperature of at least 30° C.
US Pat. No. 10,919,038

MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES

Bio-Rad Laboratories, Inc...

1. A coated polymer surface comprising:a substrate layer comprising cyclic olefin polymer (COP) or cyclic olefin copolymer (COC); and
a coating layer comprising a silicone polymer and hydrophobic silica, wherein the coating layer is adsorbed to at least a portion of the substrate layer.
US Pat. No. 10,919,807

HIGH-STRENGTH FLOWABLE FILL COMPOSITIONS

1. A high-strength flowable fill composition for backfilling a void comprising:between 60% and 90% aggregate by weight of the composition;
between 3% and 25% cement by weight of the composition;
between 5% and 25% water by weight of the composition;
between 0.05% and 5.0% coloring agent by weight of the composition;
between 0.01% and 2.0% polymer by weight of the composition; and
between 0.01% and 1.0% fibers by weight of the composition;
the composition having a compressive strength of between 10 psi and 500 psi after 1 day, a compressive strength of between 300 psi and 1300 psi after 7 days, and a compressive strength of between 1000 psi and 2500 psi after 28 days.
US Pat. No. 10,920,063

POLYMER GEL WITH NANOCOMPOSITE CROSSLINKER

Saudi Arabian Oil Company...

1. A method of making a nanocomposite, the method comprising:forming a first aqueous dispersion comprising zirconia nanoparticles and graphene oxide powder;
combining a reducing agent with the first aqueous dispersion;
irradiating the first aqueous dispersion with microwave radiation, thereby yielding a second aqueous dispersion comprising zirconia and graphene; and
separating the nanocomposite from the second aqueous dispersion, wherein the nanocomposite comprises zirconia and graphene.
US Pat. No. 10,920,064

ULTRAHIGH MELT FLOW STYRENIC BLOCK COPOLYMERS

Kraton Polymers LLC, Hou...

1. A selectively hydrogenated block copolymer having an S block and an E or E1 block and having a general formula: S-E-S, (S-E1)nX, or mixtures thereof,wherein:
n has a value of 2 to 6;
X is a coupling agent residue;
the S block has a peak molecular weight of 4,400 to 5,600 g/mol;
the block copolymer has a solution viscosity of less than 80 centipoise (cP) as measured at 25 wt. % toluene and 25° C.;
the block copolymer has a polystyrene content of 25 to 40 wt. %; and
up to 50 wt. % of diblock units in the block copolymer have a general formula S-E or S-E1,
wherein prior to hydrogenation:
the S block is a polystyrene block;
the E block is a polydiene block selected from the group consisting of polybutadiene, polyisoprene and mixtures thereof, and having a peak molecular weight of from 18,000 to 26,000 g/mol;
the E1 block is a polydiene block selected from the group consisting of polybutadiene, polyisoprene and mixtures thereof, and having a peak molecular weight of from 9,000 to 13,000 g/mol;
the polydiene block has a total vinyl content of 60 to 85%; and
wherein subsequent to hydrogenation:
0-10 percent of styrene double bonds in the block copolymer are reduced, and
at least 80 percent of conjugated diene double bonds in the block copolymer are reduced.
US Pat. No. 10,923,761

LITHIUM-ION BATTERY

CONTEMPORARY AMPEREX TECH...

1. A lithium-ion battery comprising a positive electrode plate, a negative electrode plate, a separator and an electrolyte, the positive electrode plate comprising a positive current collector and a positive film, the positive film being provided on at least one surface of the positive current collector and comprising a positive active material, the negative electrode plate comprising a negative current collector and a negative film, the negative film being provided on at least one surface of the negative current collector and comprising a negative active material;wherein
the positive active material comprises a material with a chemical formula of LiaNixCoyM1-x-yO2, M is one or two selected from Al and Mn, 0.95?a?1.2, 0 the negative active material comprises graphite;
an OI value of the positive film represented by OIc and an OI value of the negative film represented by OIa satisfy a relationship: 0.05?OIa/OIc?10;
OIc=C003/C110, C003 represents characteristic diffraction peak area of (003) crystal plane in X-ray diffraction pattern of the positive film, C110 represents characteristic diffraction peak area of (110) crystal plane in X-ray diffraction pattern of the positive film;
OIa=C004/C110, C004 represents characteristic diffraction peak area of (004) crystal plane in X-ray diffraction pattern of the negative film, C110 represents characteristic diffraction peak area of (110) crystal plane in X-ray diffraction pattern of the negative film; and
the OI value of the positive film represented by OIc is 5˜80.
US Pat. No. 10,920,321

CHROME-FREE ADHESION PRE-TREATMENT FOR PLASTICS

UAB REKIN INTERNATIONAL, ...

1. A method of pretreating a 30% glass fibers filled polyetherimide substrate for metallization, the method comprising:contacting a surface of the substrate for 10 minutes to 30 minutes with a first composition comprising nitric acid at a concentration of 10.4 Moles/L (M/L) to 13.0 M/L to form a first treated surface; and
contacting the first treated surface for 4 minutes with a second composition comprising sulfuric acid at a concentration of 16.9 M/L, and periodate ions at a concentration of 0.2 M/L, to produce an adherent surface on the substrate for metallization;
wherein the method is free of chromium ions;
the method is free of a mechanical abrasion step; and
the adherent surface upon metallization exhibits an adhesion of metal of 1.5 N/mm or greater when measured according to ASTM International Test Method B533-85 (2013).
US Pat. No. 10,920,066

RESIN COMPOSITION WITH POLYCARBONATE RESIN, ACRYLONITRILE-BUTADIENE-STYRENE RESIN, AND INORGANIC FILLER, RESIN MOLDED ARTICLE, METHOD FOR MANUFACTURING RESIN MOLDED ARTICLE, AND ELECTRONIC APPARATUS

Canon Kabushiki Kaisha, ...

8. A resin composition comprising:a polycarbonate resin, an acrylonitrile-butadiene-styrene resin, an elastomer, and an inorganic filler, wherein
when a sum of contents of the polycarbonate resin and the acrylonitrile-butadiene-styrene resin is set to 100 parts by mass, the content of the polycarbonate resin is 86 parts by mass or more and 96 parts by mass or less,
the elastomer is an acrylic block copolymer,
an aspect ratio of the inorganic filler is 3 or more, and
the inorganic filler is precipitated calcium carbonate or wollastonite.
US Pat. No. 10,919,811

ALUMINUM-SILICON-CARBIDE COMPOSITE AND METHOD OF MANUFACTURING SAME

Denka Company Limited, T...

1. An aluminum-silicon-carbide composite formed by impregnating a porous silicon carbide molded body with an aluminum alloy, whereina ratio of the silicon carbide in the composite is 60 vol % or more; and
the composite contains:
60-75 mass % of silicon carbide having a particle diameter of 80 ?m or more and 800 ?m or less;
20-30 mass % of silicon carbide having a particle diameter of 8 ?m or more and less than 80 ?m; and
5-10 mass % of silicon carbide having a particle diameter of less than 8 ?m,
wherein the aluminum-silicon-carbide composite has a thermal conductivity of 230 W/mK or more at 25° C.
US Pat. No. 10,920,067

POLYMER COMPOSITIONS CONTAINING PHOSPHATES

Rohm and Haas Company, P...

1. A polymer composition comprising:(i) one or more multistage polymers comprising
(a) a first stage polymer having a Tg of ?20° C. or lower, and
(b) a final stage polymer having a Tg of 50° C. or higher;
(ii) one or more phosphate surfactant in an amount of 50 ppm or more, based on the dry weight of the multistage polymer;
(iii) one or more alkaline phosphate in an amount of 100 ppm or more, measured as the weight of phosphorous, based on the dry weight of the multistage polymer; and
(iv) one or more phosphate salt of a multivalent cation.
US Pat. No. 10,919,812

CERAMIC POWDER AND BORON NITRIDE SINTERED MATERIAL

Sumitomo Electric Industr...

1. A method for producing a ceramic powder, comprising:heating in a purified gas, heating under low oxygen partial pressure, or treating by thermal plasma a raw ceramic powder, wherein
the raw ceramic powder contains at least one of a nitride and a carbonitride of one or more elements selected from the group consisting of a group 4 element, a group 5 element and a group 6 element,
the ceramic powder contains at least one of a nitride and a carbonitride of a metal element,
the metal element is one or more elements selected from the group consisting of a group 4 element, a group 5 element and a group 6 element, and
the ceramic powder has an average particle size of 5 ?m or less and an oxygen content of 0.1% by mass or less.
US Pat. No. 10,920,068

TWO-PACK TYPE EPOXY RESIN COMPOSITION

CEMEDINE CO., LTD., Toky...

1. A two-pack type epoxy resin composition comprising:a base material comprising:
(A) an epoxy resin,
(B) a compound having an Si—F bond, and
(C) an alkoxysilane not having at least one group selected from the group consisting of a primary amino group, a secondary amino group, and a mercapto group;
and a curing agent comprising:
(D) a crosslinkable silicon group-containing organic polymer, and
(E) a tertiary amine compound.
US Pat. No. 10,920,324

ZIRCONIUM PRETREATMENT COMPOSITIONS CONTAINING MOLYBDENUM, ASSOCIATED METHODS FOR TREATING METAL SUBSTRATES, AND RELATED COATED METAL SUBSTRATES

PPG Industries Ohio, Inc....

1. A pretreatment composition comprising:a Group IIIB and/or Group IVB metal cation;
a free fluoride source;
molybdenum in an amount of 5 ppm to 500 ppm based on total weight of the pretreatment composition; and
copper, silver, and/or gold.
US Pat. No. 10,919,814

METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS

Pivot Bio, Inc., Berkele...

1. A composition comprising:an engineered diazotroph comprising at least one genetic variation introduced in a nitrogen fixation genetic regulatory network, whereby the engineered diazotroph comprises increased expression or activity of nifH, increased expression or activity of nifA, and decreased expression or activity of nifL, wherein the at least one genetic variation comprises genetic material that originates from the same genus as said engineered diazotroph, whereby the engineered diazotroph has increased nitrogen fixation activity as compared to an unmodified organism of the same species as the engineered diazotroph; and
a plant seed.
US Pat. No. 10,920,070

POLY(BUTYLENE TEREPHTHALATE) COMPOSITION AND ASSOCIATED ARTICLE

SABIC GLOBAL TECHNOLOGIES...

1. A composition comprising, based on the total weight of the composition:98.5 to 99.5 weight percent of a poly(butylene terephthalate) having an intrinsic viscosity of 0.6 to 1.5 deciliter per gram measured 30° C. in 60:40 weight/weight phenol/tetrachloroethane;
0.05 to 0.8 weight percent of an epoxy compound having a weight average molecular weight of 1,000 to 100,000 daltons, and an epoxy equivalent weight of 400 grams to 10,000 grams per equivalent, the epoxy compound comprising a poly(ethylene-glycidyl methacrylate);
0.05 to 0.2 weight percent of a phosphorus-containing compound comprising calcium hypophosphite; and
0.2 to 1.5 weight percent of additives selected from the group consisting of stabilizers, mold release agents, and combinations thereof.
US Pat. No. 10,920,326

ETCHANT COMPOSITION FOR ETCHING TITANIUM LAYER OR TITANIUM-CONTAINING LAYER, AND ETCHING METHOD

KANTO KAGAKU KABUSHIKI KA...

1. An etchant composition for etching a titanium layer or titanium-containing layer on an oxide semiconductor, comprising an ammonium ion-containing compound, hydrogen peroxide, a basic composition, and phosphorus atom-containing oxo acid and/or an ion thereof, wherein the ammonium ion-containing compound is one or more compounds selected from a group consisting of ammonium sulfate, ammonium phosphate, ammonium acetate, ammonium nitrate, ammonium chloride and ammonium succinate, wherein the basic composition is selected from a group consisting of an inorganic alkali compound, quaternary amine hydroxide and an amine, and having pH between 7 and 11.
US Pat. No. 10,921,095

METALLIZED TEXTILE FOR MULTISPECTRAL CAMOUFLAGE

1. A metalized textile having an upper and lower surface comprising:a textile having a first side, a second side, and a plurality of yarns;
a first metalized layer covering all of the surfaces of the plurality of yarns of the textile, wherein the first metalized layer comprises a metal; and,
a second metalized layer adjacent to the first metalized layer at least partially covering the first metalized layer, wherein the second metalized layer comprises a plurality of metallic particles, binder, and a pigment, wherein the second metalized layer comprises a pattern,
wherein the pattern contains at least 2 colors, wherein at least one of the colors comprises the plurality of metallic particles and the pigment wherein at least two colors have a difference in reflectivity of at least 20% in each of the following regions: 1 ?m 2 ?m, average over 3-5 and average over 8-12 ?m.
US Pat. No. 10,919,816

EPOXIDE MOISTURE BARRIER COATINGS CONTAINING THERMOPLASTIC RESINS

SURFACE CHEMISTS OF FLORI...

15. A moisture barrier coating system comprising:A. at least one polyglycidyl ether resin, and
B. at least one epoxy curing agent comprising aminesand further comprising at least one amorphous thermoplastic material that is nonreactive with A and with B, and that forms a homogeneous mixture with at least one of A or B.
US Pat. No. 10,919,048

REAGENT SCHEME FOR SEDIMENTARY PHOSPHATE FLOTATION

ARR-MAZ PRODUCTS, L.P., ...

1. A process of phosphate flotation comprising:pulping phosphate ore with water to about 55% to 75% solids to produce an ore slurry;
conditioning the ore slurry with a reagent scheme to produce a conditioned slurry, where the reagent scheme comprises a combination of fatty acid, fuel oil, and fatty acid soap and does not comprise a pH modifier and where the pH of the ore slurry and the pH of the conditioned slurry are not modified with a pH modifier;
subjecting the conditioned slurry to flotation to produce an underflow and an overflow; and
collecting the overflow as phosphate concentrate.
US Pat. No. 10,920,073

POLYURETHANE CURABLE COMPOSITION CONTAINING POLYMER FINE PARTICLES EXCELLENT IN MECHANICAL STRENGTH

KANEKA CORPORATION, Osak...

1. A polyurethane curable composition comprising a polyol (A) and a polyisocyanate (B) as an essential component, wherein the composition comprises polymer particles (C) having a core-shell structure including at least a core layer and a shell layer,the polymer particles (C) are contained in an amount of 1 to 150 parts by mass per 100 parts by mass of a total amount of the polyol (A) and the polyisocyanate (B),
the core layer has a glass transition temperature (Tg) of more than 0° C. as calculated by the following numerical formula (1) and the core layer of the polymer particles (C) comprises a polymer polymerized with 80 to 99% by mass of a non-crosslinking monomer and 20 to 1% by mass of a crosslinking monomer,
the polyol (A) has an average hydroxyl value of 1 to 150 mgKOH/g,
a cured product formed by the curable composition has an elongation of more than 47% at a maximum tensile stress,
1/Tg=?(Mi/Tgi)  (1)
wherein Mi represents a weight fraction of the non-crosslinking monomer i constituting the core layer of the polymer particles, Tgi represents a glass transition temperature (K) of a homopolymer polymerize with the non-crosslinking monomer i, and i represents an integer of 1 or more.
US Pat. No. 10,918,024

METHOD FOR SAFE PRODUCTION OF RICE SOIL MILDLY AND MODERATELY POLLUTED BY HEAVY METALS

1. A method for safe production of rice on soil mildly and moderately polluted by heavy metals, wherein: the method comprises applying a passivator before transplanting rice seedlings to reduce activity of heavy metals in soil, and then spraying a foliar barrier from a peak tillering stage to a booting stage of rice and at a filling stage of rice;wherein the passivator is a cadmium-arsenic synchronous passivator;
the cadmium-arsenic synchronous passivator has three layers from the inside to the outside, each layer having an independent coating film; wherein the innermost layer is a hydrogen ion chemical consumer, the middle layer is a reaction accelerator humus substance, and the outermost layer is a mineralization precursor;
the hydrogen ion chemical consumer is a nitrate and a peroxide;
the reaction accelerator humus substance is one or more of peat soil, humic acid, fulvic acid, humin, ulmic acid and humus acid; and
the mineralization precursor is reducing iron powder, a ferrous salt and/or a solid ferrous mineral.
US Pat. No. 10,920,332

PROCESS FOR THE PREPARATION OF CORROSION RESISTANCE SEALED ANODIZED COATINGS ON ALUMINUM ALLOY

Council of Scientific and...

1. An improved process for the manufacture of a corrosion resistant, sealed, anodized, coated metal or metal alloy substrate, the process comprising the steps of:(a) cleaning a metal or metal alloy substrate by wiping with acetone or ultrasonication;
(b) rinsing the cleaned substrate of (a) with distilled water;
(c) etching the rinsed substrate of (b) in sodium hydroxide solution having a concentration between 0.3 to 1 molar;
(d) rinsing the etched substrate of (c) with distilled water;
(e) deoxidizing the rinsed substrate of (d) in a 1:1 aqueous solution of nitric acid followed by rinsing with distilled water;
(f) forming an anodic oxide coating on the deoxidized substrate of (e) by anodization;
(g) sealing the anodic oxide coating on the substrate of (f) in a sealing bath containing a solution comprising as corrosion inhibitors, a combination of manganese oxyanions in the range of 2 to 17 g/l and vanadium oxyanions in the range of 1 to 10 g/l, and as an additive, one or more alkali metal nitrates in the range of 3 to 8 g/l, followed by rinsing with distilled water; and
(h) air drying the substrate having the sealed anodic oxide coating of (g) to form the corrosion resistant sealed, anodized, coated substrate,
wherein the anodization in (f) is performed in an 8 wt % tartaric acid-2.5 wt % sulphuric acid electrolyte at a temperature in the range of 28-30° C. and with current densities between 10 to 30 mA/cm2 for a period of 30 to 120 minutes, and
wherein the sealing in (g) is performed by dipping the substrate with the anodic oxide coating from (f) in the sealing bath containing the solution comprising as corrosion inhibitors, a combination of manganese oxyanions in the range of 2 to 17 g/l and vanadium oxyanions in the range of 1 to 10 g/l, and as an additive, one or more alkali metal nitrates in the range of 3 to 8 g/l, for a period from above 20 up to 40 minutes at a pH in the range 7 to 9 and at a temperature between 60 and 80° C.
US Pat. No. 10,920,077

CONDUCTIVE SILICONE COMPOSITION AND SILICONE COMPOSITE MATERIAL MANUFACTURED THEREBY

LG CHEM, LTD, Seoul (KR)...

1. A conductive silicone composition comprising:a catalyst-type conductive rubber composition containing 100 parts by weight of catalyst-type liquid silicone and 0.5 to 2.5 parts by weight of carbon nanotubes; and
a crosslinking-type conductive rubber composition containing 100 parts by weight of crosslinking-type liquid silicone and 0.5 to 2.5 parts by weight of carbon nanotubes, wherein
the initial viscosity of each of the catalyst-type liquid silicone and the crosslinking-type liquid silicone is 5,000 to 41,000 CP,
the average viscosity of the conductive rubber compositions is 80,000 to 350,000 cP,
the viscosity difference between the initial viscosity of the liquid silicones and the average viscosity of the conductive rubber compositions is 70,000 to 310,000, and
the viscosity was measured at a temperature of 25° C. and a shear rate of 10 s?1.
US Pat. No. 10,921,615

GREY COMPOUNDED INFRARED ABSORBING SPECTACLES, GOGGLES, FACESHIELDS AND HOOD WINDOWS USED IN PERSONAL PROTECTIVE EQUIPMENT FOR ARC FLASH HAZARDS

Oberon Company Div Paramo...

1. A faceshield for blocking arc flash thermal energy including infrared energy, the faceshield comprising:a lens providing color acuity within the visible light spectrum, wherein the lens provides at least 44% light transmission across the visible light spectrum, the lens comprised of antimony doped particulate that blocks infrared radiation, and an optically clear plastic material, the optically clear plastic material and the particulate chosen and blended in proportion so that the faceshield will block a range from 3 to 40 cal/cm2 of arc flash thermal energy, the lens further comprising of:
a) an optically clear plastic material selected from the group consisting of but not limited to polycarbonate, acrylic, cellulose propionate, cellulose acetate and cellulose acetate butyrate; and
b) a particulate consisting essentially of an antimony doped tin oxide coated with a dispersant wherein the antimony doped tin oxide coated with a dispersant has a size range of about 5 to 15 microns per particle; and
c) the particulate described in b) dispersed within said optically clear plastic material.